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BSA  Bovine serum albumin 
C Cytosine 
C57BL/6 C57 black 6 (mouse strain)
CDK Cyclin-dependent kinase
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cis-DDP cis-Dichlorodiammineplatinum(II) or cisplatin
CSA Cockayne syndrom protein A
CSB Cockayne syndrom protein B
CTR1 Copper transport protein 1
Cy3 Cyanine 3 
DAPI 4',6-Diamidino-2-phenylindole
DDB Damaged DNA binding protein  
DIPH Diphenylhydramine hydrochloride
DMEM Dulbecco's modified Eagle's medium
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
dNTP Desoxyribosenucleotide triphosphate
DRG Dorsal root ganglion
DSB Double strand breaks
EDTA Ethylendiaminetetraacetic acid
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EM Electron microscopy
ERCC Excision-repair cross-complementing protein  
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FACS Fluorescence-activated cell sorting
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FCS Fetal calf serum
Fig. Figure 
FITC Fluorescein isothiocyanate
G Guanine 
GADD45 Growth arrest and DNA damage protein 45
GGR Global genome repair
GSH Glutathione 
GTP Guanosine triphosphate
H2AX Histone H2AX
HC Hair cell 
H&E Haematoxyline and eosin
HHR23 Human homologue of RAD23 
HMG High mobility group 
hUBP Human upstream binding factor
i.e. Id est 
IFZ Institute für Zellbiologie (Institute for Cell Biology) 
Ig Immunoglobulin
IHC Inner hair cell
i.p. Intraperitoneal
ICA Immunocytological assay
K-ras V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LD50 50% of the lethal dose
MAB Monoclonal antibody
MC Marginal cells
MDCK Madin-Darby canine kidney cells
MRP Multidrug resistance-related protein
Max. Maximal 
MLH MutL homolog protein
MMR Mismatch Repair
M-phase Mitosis phase
MSH MutS homolog protein
MT Mitochondria
MW Molecular weight
NAD+ Nicotinamide adenine dinucleotide
NER Nucleotide excision repair
NHEJ Non-homologous end joining
NSCLC Non-small cell lung cancer
OAT Organic anion transporter
OATP Organic anion transporting polypeptides
OCT Organic cation transporter
OCTN Organic cation ergothioneine/carnitine transporter 
OHC Outer hair cell
PARP Poly-(ADPribose)-polymerase
PBS Phosphate-buffered saline
PBST Phosphate-buffered saline plus Tween20
PCNA Proliferating cell nuclear antigen
PCR Polymerase chain reaction
PEPT Peptide transporter
PFA Paraformaldehyde
PgP P-glycoprotein
PS Phosphatidyl serine
PTC Proximal tubule cell
Pt-GG Cisplatin-G:G intrastrand crosslink (Pt-1,2-d(GpG) adducts)
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Pt-SH Inactive glutathione-cisplatin complex
RFC Replication factor C
RM Reissner’s membrane
RNA Ribonucleic acid
RNA pol II RNA polymerase II
ROS Reactive oxygen species
RPA Replication protein A
RPMI Roswell Park Memorial Institute medium
RT Room temperature
SC Supporting cell
SD Standard deviation
SDS Sodium dodecyl sulfate
S-Phase DNA synthesis phase 
SRY Sex-determining region Y protein
S-S Sulfhydryl group
SSC Saline sodium citrate buffer
T Thymine 
TAE Tris-acetate-EDTA
TBP TATA binding protein
TCR Transcription-coupled repair
TE Tris-EDTA 
TFIIH Transcription factor IIH
TKPTS Proximal tubule cell line derived from mouse
Tris  Tris(hydroxymethyl)aminomethane 
Tween 20  Polyoxyethylene sorbitan monolaurate 
URAT Urate transporter
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XAB2 XPA-binding protein 2
XP Xeroderma pigmentosum
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1. Introduction 
 
1.1 Historical perspective of cisplatin discovery 
 
The inorganic platinum complex cisplatin (cis-dichlorodiammineplatinum(II) or cis-
DDP) is a well-known and widely-used antineoplastic drug, and has been used in the 
clinic for more than 40 years. This compound was first synthesized in 1840 by 
Peyrone (Peyrone, 1844). However, its antineoplastic activity remained unnoticed for 
120 years. The physicist Barnett Rosenberg accidently observed that cisplatin 
inhibited the proliferation of Escherichia coli cells and provoked filamentous growth of 
bacterial cells (Rosenberg et al., 1965; Rosenberg et al., 1969).  
Since its biological properties were first tested on tumors in 1971 (Rossof, et al., 
1972; Rosenberg et al., 1977; Hill et al., 1982), cisplatin has become one of the most 
used drugs in the treatment of solid tumors of epithelial origin. Although cisplatin has 
been a mainstay for testicular cancer therapy (Oliver et al., 1993; Einhorn, 1997), it is 
also commonly used to treat ovarian, cervical, bladder, and non small cell lung 
carcinoma as well as head and neck cancers (Sleijfer, Meijer and Mulder, 1985; 
Berclaz et al., 2002; Armstrong et al., 2006; Helm and States, 2009; Konstantakou et 
al., 2009).  Cisplatin is also successfully used in the treatment of paediatric 
malignancies, such as medulloblastoma and osteogenic sarcoma (Saeter et al., 
1999; Kortmann et al., 2003). In most recent treatment schedules, the drug is used in 
combination with other cytotoxic agents such as otoposide, paclitaxel, doxorubicine, 
5-fluorouracil, gemcitabine, vinblastine, bleomycin and other (Schiller et al., 2002; 
Lee et al., 2006; Armstrong et al., 2006; Kang et al., 2008; de La Motte Rouge et al., 
2008; Perilongo et al., 2009).  
In spite of the clinical success of cisplatin, repetitive treatment often has to be 
discontinued at a certain stage. The two limiting factors for a successful application of 
cisplatin are acquired or intrinsic drug resistance of the tumor and severe side effects 
in normal tissues, mainly in the kidney, in the inner ear and in the peripheral nerves 
(Siddik, 2003; Kelland, 2007; Pabla and Dong, 2008). New platinum analogs, such as 
carboplatin and oxaliplatin, were synthesized to avoid these factors. Unfortunately, 
both of them have severe and dose-limiting side effects as well. Carboplatin and 
especially oxaliplatin have prominent neurotoxic effects, but do not induce 
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considerable ototoxicity or nephrotoxicity (Screnci and McKeage, 1999). In contrast 
to oxaliplatin, carboplatin additionally displays prominent toxicity in the hematopoietic 
system. The mechanisms of the noted differences in side effects are still not fully 
understood. 
 
1.2 Chemistry of cisplatin  
 
Cisplatin is a small, uncharged platinum complex (molecular weight: 300 g/mol; Fig. 
1) with two chloride ligands. The compound is rather stable and inert as long as it is 
in a high chloride environment, such as in the blood stream (150 mM). When entering 
the cell, where chloride concentrations are as low as 5 mM, the ligands of cisplatin 
are sequentially exchanged by water molecules forming so-called highly reactive 
positively charged aqua complexes, which can be either monohydrated 
[Pt(NH)Cl(OH)] or dihydrated [Pt(NH)(OH)] (Fig. 1; Wang and Lippard, 2005).  
 
  
 
 
Fig. 1: Cisplatin and its products of hydrolysis. In cisplatin the platinum atom has the oxidation 
state +2 and its chloride  ligands can sequentially be displaced e.g. by water molecules to form aqua 
complexes.  
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Both positively charged hydrated forms of cisplatin are electrostatically attracted by 
negatively charged macromolecules in the cell, such as DNA, and thereby, facilitating 
the reaction with nucleophilic centers like the N7 atom of guanine (Wang and 
Lippard, 2005). Due to the presence of two potentially reactive sites, cisplatin is a 
bifunctional drug enabling the formation of covalent crosslinks between two 
molecules.   
  
1.3 Mechanisms of cytotoxic action 
 
The exact molecular mechanism of the cytotoxicity induced by cisplatin is still 
unknown, but it is generally accepted that the primary target for the drug is nuclear 
DNA. However, a number of other modes of action have also been suggested (Fig. 
2). 
 
 
Fig. 2: Cytotoxic mechanisms of cisplatin: possible targets. Once inside the cell, cisplatin has a 
number of possible targets: DNA, RNA, sulfur-containing enzymes and mitochondria. 
 
There are several reports on the interaction of cisplatin with RNA, proteins involved in 
antioxidant systems, cell signaling, cell metabolism and mitochondrial DNA. Those 
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reactions may induce apoptosis, necrosis or autophagy, as cell death pathways 
(Jordan and Carmo-Fonseca, 1998; Yang et al., 2006; Cullen et al., 2007; Inoue et 
al., 2009).  
However, the induction of apoptosis in tumor cells is believed to be the reason for the 
antineoplastic effect of cisplatin in cancer chemotherapy (Dive and Hickman, 1991). 
Binding of cisplatin to mitochondrial DNA leads to necrosis rather than to apoptosis 
(Troyano et al., 2001). 
 
1.3.1 DNA damage 
 
Upon binding to DNA, cisplatin forms adducts, which are chemical modifications 
altering the structural integrity of the DNA molecule. Among those adducts, the most 
frequent structures are intrastrand crosslinks between adjacent guanines (Pt-GG), 
making up about 65% of all adducts formed after cisplatin exposure (Fig. 3). 
Crosslinks between neighbouring adenine and guanine bases (Pt-AG) rank second 
with 25%. In addition, a few other types of adducts have been identified in cisplatin-
exposed DNA, but they are formed at rather low frequencies. Among them are (G-X-
G) intrastrand crosslinks bridging one unaffected base (X) in between two guanines, 
and (G-G) interstrand crosslinks that react with the N7 positions of two guanines in 
opposite strands. At least transiently, cisplatin also induces monoadducts by reacting 
only at one active site with a nucleophilic position in DNA.  Such adducts can lead to 
DNA-protein crosslinks when the second active position interacts, for example, with a 
sulfhydryl or disulfide (S-S) groups. When cisplatin is “activated”, the formation of 
monoadducts is a rather fast process, whereas the secondary formation of crosslinks 
is comparably slower, taking hours. 
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Fig. 3: Schematic overview of cisplatin interactions with DNA. Various types of cisplatin–DNA 
complexes or adducts can be formed. The most frequently observed adducts are intrastrand links 
between adjacent guanines (65%) or links between adenine and guanine (25%). Cisplatin can also 
stretch across a base to join two guanines (GXG) on the same strand of DNA. Cisplatin can also join 
bases across the two DNA strands (interstrand adducts) or can form monoadducts when only one of 
the reactive arms is bound to DNA. Such adducts can lead to crosslinks between DNA and proteins or 
other molecules e.g. glutathione (adopted from Master and Köberle, 2003). 
 
 
1.3.2 Recognition of cisplatin-DNA adducts 
 
As mentioned above, cisplatin preferentially binds to DNA on adjacent guanines in 
the major groove of the helix leading to a significant bending towards the major 
groove and exposing the minor groove to several classes of DNA-binding proteins 
(Bellon et al., 1991). These include the TATA-binding protein (TBP), the sex-
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determining region Y protein (SRY), the human upstream binding factor (hUBP), high 
mobility group 1 (HMG1) and group 2 (HMG2) proteins, histone H1, a number of DNA 
repair proteins and transcription factors (Gniazdowski and Czyz, 1999; Kartalou and 
Essigmann, 2001; Wozniak  and Blasiak, 2002). Binding of such proteins to cisplatin-
modified sites further enforces the bending of the DNA. The recognition and binding 
of cellular proteins to cisplatin-damaged sites is not sequence-specific. The 
“architectural” proteins HMG1/2 recognize the distortions of the DNA helix as natural 
binding sites (Chow et al., 1995).  
 
1.3.3 DNA repair of cisplatin adducts 
 
All living organisms are able to counteract structural alterations in their genome and 
nucleotide excision repair (NER) is the main mechanism by which cisplatin-induced 
damage is removed in mammalian cells (Masters and Köberle, 2003). In sum, 11 
proteins from the NER family are involved in recognizing and removing cisplatin 
adducts. First, a dimeric complex of XPC and HHR23 binds to DNA, altering its 
structure and allowing access of other repair proteins. In the next step, RPA, XPA, 
and TFIIH attach to the distorted DNA. Two DNA helicases, XPB and XPD, unwind 
DNA at the site of damage and several nucleotides further in both directions. Two 
endonucleases cut out 24-32 base-long oligonucleotides. XPG cuts the 3’-end of the 
lesion, XPF in complex with excision repair cross-complementing-1 (ERCC1) cuts the 
5’-end. The deleted segment is then replaced by DNA polymerase gamma or eta in 
complex with PCNA and RFC. After the segment is synthesized, the DNA-ligase 
connects it to the repaired strand of DNA (Masters and Köberle, 2003). Alternatively, 
platinum adducts can be removed in actively transcribing genes efficiently by a 
specialized sub-pathway of the NER called transcription-coupled repair (TCR) (Fig.4). 
The activation of mismatch-repair and recombination repair mechanisms on cisplatin 
damage have also been reported (Firk et al., 1996; Mello et al., 1996; Zdraveski et 
al., 2000).  
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Fig. 4: Schematic model of the two sub pathways of nucleotide excision repair (NER) in 
mammals. The transcription-coupled repair (TCR) accomplishes fast removal of transcription-blocking 
lesions in comparison to the slower global genome repair (GGR) pathway. The XPA protein is involved 
in both sub pathways. After damage recognition by the XPC protein in GGR, or by the RNA 
polymerase II in TCR, the XPA protein binds to the damaged site and recruits other proteins to build a 
repair complex. (Figure from www.imcb.osaka-u.ac.jp/en/seminar/03a.html). 
 
 
 
1.3.4 Cell cycle arrest and transduction of DNA damage signals 
 
In vitro studies have shown that cisplatin is not a cell cycle phase-specific drug and 
cancer cells are responsive in different cell cycle phases (Sekiguchi et al., 1996). 
However, cells are more sensitive to the drug in the G2/M-phase than in other 
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phases. After exposure to cisplatin, most cells pass slower through the S-phase and 
stop cycling at the G2-M transition. The fate of the cell then depends on the type and 
level of nuclear DNA adducts remaining unrepaired at this point of the cycle. Cells 
can either proceed with mitosis or induce apoptotic mechanisms.  
Several cellular pathways have been reported to be involved in transducing signals 
from cisplatin-induced DNA damage to downstream mechanisms like cell cycle 
arrest, apoptosis or necrosis (Wang and Lippard, 2005). However, most of the  
studies showed controversial results, and taken together, the main conclusion  is that 
the specific response to the genotoxic stress is strongly related to the origin and the 
particular nature of the cell line analyzed (Theis and Roemer, 1998; Wang et al., 
2000; Cui et al., 2000; Kigawa et al., 2002; Levresse et al., 2002; Fraser et al., 2003; 
Machuy et al., 2004). 
 
1.3.5 Induction of cell death 
 
There are three main mechanisms of cell death after exposure to cytotoxic agents:  
programmed cell death (apoptosis), disorder cell death (necrosis) and autophagic cell 
death (Kroemer et al., 2005; Klionsky and Emr, 2000). Cisplatin has been reported to 
induce all three types of destruction (Gonzalez et al., 2001; Inoue et al., 2009).  
It is widely accepted that cancer chemotherapy with platinum-based drugs 
predominantly triggers apoptosis in cycling tumor cells via the intrinsic pathway by 
the release of cytochrome c from mitochondria and a subsequent activation of 
caspase-9 (Li et al., 1997).  There is also evidence that caspase-3 is critical for 
cisplatin-induced apoptosis (Blanc et al., 2000).  
 The mechanisms by which cisplatin induces functional loss and structural ruin in 
differentiated, non-dividing normal cells are much less clear. Most studies in this 
respect have been performed with kidney proximal tubule cells because these cells 
are the “target” of the cisplatin-induced nephrotoxicity in vivo and they are highly 
sensitive to the drug in vitro and in vivo (Lieberthal et al., 1996). 
Caspase-9 activation was shown not to be necessary for the induction of apoptosis in 
these cells (Cummings and Schnellmann, 2002). Instead, Fas and the Fas ligand 
were found to be upregulated by cisplatin (Fulda et al., 1998). Excessive DNA 
damage induces hyper-activation of Poly (ADP-ribose) polymerase (PARP). PARP 
cleaves NAD+ and transfers ADP-ribose moieties (ADPR) to carboxyl groups of 
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nuclear proteins, thereby causing NAD+/ATP depletion and resulting in necrosis 
(Herceg and Wang, 2001; Wang  and Lippard, 2005).  
Autophagy is a mechanism to degrade cellular components such as organelles, 
protein aggregates and other macromolecules. Under normal conditions, the activity 
of this mechanism in cells is quite low, but can be strongly upregulated during 
starvation or other types of cell stress. Treatment with DNA-damaging agents like 
cisplatin represents such a stress condition. Normally, autophagic processes promote 
cell survival under unfavorable conditions, but if such a condition persists over time, 
autophagy can lead to complete cell degradation (Kroemer and Levine, 2008). It is 
generally assumed that autophagic processes regulate the balance between cell 
death and survival and that dividing cells actively undergo apoptosis, whereas G0 
cells die with signs of necrosis. Several studies have demonstrated autophagy to 
occur during cisplatin treatment in kidney proximal tubule cells (Periyasamy-
Thandavan et al., 2008; Inoue et al., 2009). The relative importance of this process 
for the distinct nephrotoxicity of the drug, however, is not yet clear. It has to be 
studied in more detail whether in this context autophagy is a mechanism for 
mediating cell death or for promoting cell survival (Spano et al., 2008; Lieberthal, 
2008). 
 
1.4 Factors limiting the therapeutic efficacy of cisplatin 
 
1.4.1 Drug resistance 
 
The acquired clinical non-responsiveness of tumors to cisplatin chemotherapy can be 
caused by a wide variety of mechanisms. Basically, such factors can be separated 
into two groups. In the first group both systemic and cellular mechanisms lead to 
reduced levels of platinum adducts in the nuclear DNA of malignant cells. 
Alternatively or concomitantly, drug resistance can also be due to increased cellular 
tolerance to such adducts by alterations in downstream signaling pathways (Fig. 5).  
 
1.4.2 Resistance through poor DNA platination 
 
Cisplatin is believed to be taken up by cells both via active transport and via passive 
diffusion. In recent years, active transport of cisplatin has been discussed as the 
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main entry mechanism of cisplatin into cells. The exact transporter or channel is 
currently unknown, but the expression of some transporters correlates well with 
tumor resistance (for example copper transporter CTR1). Decreased expression of 
CTR1 on the membrane of the cell can reduce the entry of cisplatin and, thereby, 
help cells to escape being killed (Ishida et al., 2002). Another way to increase the 
cellular resistance to cisplatin is the active export by suitable transporters before its 
interaction with the nuclear DNA. These transporters are also not known, but some 
suggest ATP7A and ATP7B for many tumors (Samimi et al., 2003; Furukawa et al., 
2008). It is important to mention here that the reported import and export channels 
modulate the accumulation of cisplatin as well as carboplatin. The tumors that are 
resistant to cisplatin via such transport mechanisms are cross-resistant to carboplatin 
as well. A third possible mechanism for cisplatin resistance is based on the 
intracellular detoxification and metabolic modification of cisplatin, or on its binding to 
other molecules, preventing the reaction with DNA. Such binding may occur when 
cisplatin encounters glutathione or other sulphur-containing peptides (Yang et al., 
2006). Cisplatin-glutathione complexes are more anionic and can be more easily 
exported out of the cell (Ishikawa, 1992). 
 
1.4.3 Resistance through altered processing of platinum-DNA adducts 
 
Once activated by the formation of aqua complexes (see 1.2), cisplatin is able to bind 
to DNA and form adducts. Resistance of tumor cells to the drug can be mediated by 
accelerated repair of such adducts (Johnson et al., 1994; Kelland, 2007).  
Augmented DNA repair capacity by overexpression of the NER component ERCC1 
was suggested to contribute to the clinical resistance of lung and ovarian tumors to 
cisplatin-based chemotherapy (Reed, 2005). Loss of DNA mismatch repair pathways 
has been reported in cisplatin resistance as well (Fink et al., 1996; Helleman et al., 
2006). Clinical studies with ovarian cancer patients have demonstrated that loss-of-
function of the DNA mismatch-repair pathway through hypermethylation of the 
hMLH1 gene after cisplatin chemotherapy might contribute to the acquired resistance 
and predicts poor survival (Gifford et al., 2004). The other resistance mechanisms 
are increasing in tolerance to platinum DNA adducts. Among them is the possibility of 
replicative bypass, whereby specialized DNA polymerases can override cisplatin-
damaged sites via translesion synthesis. The functional inhibition of such 
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polymerases has been shown to sensitize cancer cells to cisplatin cyctotoxicity in 
vitro (Albertella et al., 2005). Finally, drug resistance can be due to the loss of 
signaling from DNA damage to cell death pathways caused, for example, by mutation 
or decreased expression of proapoptotic proteins (Kelland, 2007). 
 
 
 
Fig. 5: Possible mechanisms of cisplatin resistance or sensitivity. Given the fact that cisplatin 
cytotoxicity results from the formation of DNA adducts, anything that decreases the cytoplasmic or 
nuclear concentration of the drug can be expected to render it less effective and the cell more 
resistant. GSH: glutathione; MT: mitochondria; Pt-SG: inactive glutathione-cisplatin complex. 
 
 
1.4.4 Dose-limiting cytotoxic side effects of cisplatin in physiological cells 
 
The second major obstacle limiting successful chemotherapy with platinum-based 
drugs is their severe systemic toxicity in normal tissues. During the treatment of 
patients with cisplatin, a typical pattern of side effects that includes nephrotoxicity, 
neurotoxicity and ototoxicity is frequently observed. Interestingly, in strict contrast to 
the antineoplastic activity, this type of damage occurs in cells which are assumed to 
be terminally differentiated and are in the non-proliferative G0 phase.  
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Neurotoxicity. Cisplatin-induced neurotoxicity commonly manifests as peripheral 
sensory neuropathy and is irreversible in most cases. The central nervous system is 
not affected because cisplatin does not readily penetrate the blood-brain-barrier, 
resulting in low DNA adduct levels (Dzagnidze et al., 2007). In contrast, peripheral 
neuronal structures, in particular the dorsal root ganglia (DRG) that contain the 
primary sensory neurons, are highly adducted after systemic application of cisplatin 
(Windebank et al., 1996; Windebank et al., 2002). Repetitive treatment cycles result 
in structural impairment of DRG cells as well as in the loss of sensory function, 
neuropathic pain, severe ataxia and weakness (Umapathi and Chaudhry, 2005; 
Visovsky, 2003). Although it has been demonstrated in transgenic mouse models that 
the accumulation of Pt-GG adducts in DRG neurons are the trigger for the onset of 
cisplatin neurotoxicity (Dzagnidze et al., 2007), and that this process is accompanied 
by massive mitochondrial damage (Yoon et al., 2009), the exact molecular 
mechanism and the reason why DRG cells are the main target structures is still not 
fully understood.  
Nephrotoxicity.  Urinary excretion is the main route of removing cisplatin from the 
organism, and severe nephrotoxicity was already described in early clinical studies 
(Gonzales-Vitale et al., 1977; Dentino et al., 1978; Madias and Harrington, 1978). 
Unbound cisplatin is freely filtered at the glomerulus and is taken up into proximal 
tubular cells, which reabsorb filtered physiological ions by active transport. 
Morphological and biochemical studies revealed structural damage after cisplatin 
treatment, predominantly in proximal tubular cells, together with increased urinary 
creatinine values and failed resorption of magnesium, sodium and potassium. Today, 
this problem is moderated in the clinic by intravenous saline volume expansion and 
by mannitol-stimulated diuresis (Finley et al., 1985; Bajorin et al., 1986; Cornelison 
and Reed, 1993). 
Ototoxicity. Ototoxicity leads to the functional impairment and cellular degeneration 
of the tissues of the inner ear, and is caused, among others, by therapeutic agents 
(Rybak and Ramkumar, 2007). The most common drugs with ototoxic side effects are 
macrolide and aminoglycoside antibiotics, cisplatin and loop diuretics (Arslan et al., 
1999). It is interesting that all these drugs also display a nephrotoxic potential, 
indicating that the causative mechanisms of oto- and nephrotoxicity might be identical 
or at least similar. Cisplatin-induced ototoxicity manifests as sensorineural hearing 
loss beginning in the high frequencies and progressing towards the speech frequency 
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range (Rybak et al., 2007). Usually, the hearing loss is bilateral and often 
accompanied by transient or permanent tinnitus, and the degree of hearing loss is 
roughly correlated to the cumulative dose of the drug (Simon et al., 2002; Bertolini et 
al., 2004). 
Today, cisplatin ototoxicity is the main cause of drug-induced hearing loss in 
Germany and other countries.  
 
1.4.5 Inter-individual variability  
 
Audiometric studies have disclosed hearing problems in 75-100% of all patients 
treated with cisplatin and a high inter-individual variability in the severity of the 
ototoxic effect (Rybak et al., 2007). The sensitivity to cisplatin is more pronounced in 
elderly and paediatric patients with children under 5 years representing the most 
susceptible group (Li et al., 2004).  The cause of the inter-individual sensitivity is not 
known, but possible explanations include genetic factors, pharmacokinetic 
differences and the metabolic status, such as a limited availability of glutathione for 
the intracellular detoxification of cisplatin (Oldenburg et al., 2007). 
 
1.5 The sense of hearing 
 
The sense of hearing is absolutely important for a human to lead a normal life. 
Communication skills are very dependent on hearing, as are basic survival skills in 
the modern world. Children who lose their hearing at an early age cannot speak 
appropriately.  In losing their ability to hear other people, they also lose the ability to 
control their own voice and to speak in such a manner that would be understandable 
to other people.  
 
1.5.1 Anatomy and physiology of hearing 
 
The human ear is a mechanoreceptor organ which detects sound signals in a broad 
range between 20 Hz and 20 kHz and the unit used for expressing the hearing 
threshold is decibel (dB). Once a sound wave reaches the external ear, it continues 
through the ear canal to the tympanic membrane, where it transmits the wave to the 
middle ear ossicular chain and on to the cochlear fluids (Fig. 6).  
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The inner ear is one of the three parts of the hearing and vestibular system (external 
ear, middle ear and inner ear, Fig.6). It consists of two parts: the cochlea, which is 
dedicated to the hearing, and the vestibular portion, which is dedicated to the balance 
(Dallos et al., 1996). The cochlea is responsible for converting sound vibrations into 
nerve impulses. The inner ear fluids transmit the mechanical waves to the primary 
sensory cells – the outer and inner hair cells. The movement of the hair bundles on 
the hair cells leads to the depolarisation of inner hair cells and to the release of 
neurotransmitters which, in turn, stimulate associated nerve endings (Fig. 7).  
The membranous labyrinth in the cochlea of the inner ear forms three compartments: 
the scala vestibuli, the scala media, and the scala tympani (Fig. 7). The scala 
tympani and the scala vestibule are filled with perilymph. The composition of this fluid 
is very similar to the composition of extracellular liquids - low in potassium (3 mM) 
and high in sodium (154 mM).  The concentration of chloride anions is similar to that 
in plasma (128 mM). In the context of this study this is important because high 
concentrations of chloride anions prevent the activation of cisplatin. The second 
important anion in the perilymph of the scala tympani is bicarbonate with a 
concentration of 20 mM. The composition of the fluid in the scala media, the 
endolymph, is nearly inverse to the sodium-potassium ratio in the perilymph - low in 
sodium (1 mM) and high in potassium (161 mM). The chloride concentration is similar 
to the perilymph (131 mM). The perilymph has a positive potential of about +80 mV, 
whereas the hair cells and the cells of the stria vascularis carry a negative potential, 
which is higher than in other surrounding cells (Konishi et al., 1978; Offner et al., 
1987).  
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Fig. 6: The structure of the external, middle and inner ear. The ear has three morphological and 
functional sections: the external ear, the middle ear, and the inner ear. The external ear collects sound 
waves and funnels them down the ear canal, where they vibrate the eardrum. Within the middle ear, 
the eardrum is connected to the middle ear bones which mechanically carry the sound waves to the 
oval window of the inner ear. The cochlea, as part of the inner ear, is a snail-like structure divided into 
three fluid-filled parts. (Figure from www.topnews.in). 
 
 
 
 
 
Fig. 7: Schematic diagrams illustrating the anatomy of the cochlea. (Figure from Wangeman, 
2006). 
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The homeostasis of ion concentrations in the inner ear is very important for the 
appropriate translation of sound waves into neuronal signals (Fig. 8). Therefore, all 
substructures of the cochlea are equipped with numerous membrane transporters to 
keep the cells prepared for the next sound stimulus. Chloride and sodium ions have 
to be recycled quickly within the system during the hearing processes. The difference 
in cellular and endolymph concentrations creates a potential difference, which 
transmits signals from outer hair cells to inner hair cells and then as electro-chemical 
signals to the spiral ganglia. Sound waves, by moving the tectorial membrane 
connected to the stereocilia, change the microfilament structure of the hair cells, 
opening apical mechano-sensitive channels on the surface of the outer hair cells, 
thereby creating electromechanical amplification of the acoustic vibrations. The 
polarisation that occurs is transmitted to the inner hair cells, which export ions out to 
the endolymph and to other cells of organ of Corti – mostly to the Deiter’s cells (a 
type of supporting cells). From these cells, the ions are recycled for another round of 
secretion to the stria vascularis through the next layer of supporting cells and the 
fibrocytes of the spiral ligament. In turn, potassium is secreted back into the 
endolymph by the marginal cells of the stria vascularis (Offner et al., 1987). 
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Fig. 8: Potassium recycling in the scala media of the inner ear. (A) K+ excreted from the hair cells 
is picked up by Deiters’ cells. K+ is then circulated to the type II and IV fibrocytes in the spiral ligament 
through the "epithelial gap-junction network," which is composed of the epithelial and supporting cells 
(purple) on the basilar membrane (dark gray) and the outer sulcus cells (purple) in the ligament. K+ is 
taken up by the types II and IV fibrocytes in the spiral ligament and transported to the stria vascularis 
via the "connective-tissue gap-junction network" comprising the fibrocytes, basal cells, and 
intermediate cells (see details in B). K+ is finally released to the endolymph in the scala media across 
the luminal site of the stria vasuclaris. The concentration of K+ and the potential of each cochlear fluid 
are indicated. (B) Ion-transport apparatuses expressed in the stria vascularis and the spiral ligament 
that participate in cochlear K+ circulation. The potential and concentration of K+ in each compartment 
are indicated. I-V: type I-V fibrocytes; NKCC1: Na+-K+-2Cl– cotransporter; TJ: tight junctions. (Figure 
adopted from Hibino and Kurachi, 2006). 
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In drug-induced ototoxicity, this balance of ions is disturbed due to the degradation of 
hair cells and marginal cells, and the potential of outer hair cells is reduced. These 
changes lead to a weaker responsiveness to sound pressure.  
 
1.6 Oto- and renoprotective strategies tested so far 
 
Since cisplatin has been used in the clinic for a long time, a plethora of 
pharmacological protective strategies to counteract the side effects have been 
attempted. These strategies based on different effects of cisplatin on the cells and 
tissues such as drug uptake, activation, metabolism, excretion, oxidative stress, cell-
cycle arrest, signalling, inflammation (Jones et al., 1992; Santoso et al., 2003; Ludwig 
et al., 2004; Badary et al., 2005; Durak et al., 2002; Lynch et al., 2005; Karimi et al., 
2005; Nagothu et al., 2005; Jo et al., 2005;). However, the rational preventive 
treatment till now has not been discovered mainly because interaction of such 
preventive treatment with antineoplastic function of cisplatin. 
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1.7 Aim of the study 
 
Despite more than 40 000 scientific publications on cisplatin during the last four 
decades, the precise mechanisms of how primary tumor cells escape in vivo from 
being eradicated by cisplatin-based chemotherapies as well as why particular 
terminally differentiated normal cells become highly vulnerable targets for the 
cytotoxic effects of the drug are still obscure. This lack of knowledge is mainly due to 
the predominant use of cell culture systems and the unavailability of analytical tools 
to measure structurally defined reaction products of cisplatin in individual cell nuclei. 
After a monoclonal antibody-based detection system for such DNA adducts was 
established in our group those two important questions were addressed in this study 
by employing a panel of mouse models. The experiments should reveal the 
pharmacodynamic mechanisms underlying the pronounced oto- and nephrotoxicity of 
cisplatin and the role of DNA platination products as the initial molecular triggers for 
the induction of cell damage and functional loss in the target tissues.  
Based on that knowledge, it was tried to develop a new pharmacological strategy to 
efficiently suppress the side effects of cisplatin in mice without reducing its 
antineoplastic efficacy.  
A further aim of this study was to elucidate the role of cellular DNA repair for the 
onset of drug resistance in a mouse model of primary lung cancer. 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Equipment 
 
Equipment Company 
ABR recording modified clinical potential system NeuroScreen Plus 
ACAS 6.0 Cytometry Analysis System Ahrens Electronics 
Adhesion slides ImmunoSelect Squarix Biotech 
Agarose Gel Chamber PEQLab  
Axioplan Fluorescence microscope Zeiss 
Centrifuge Rotina 48  Hettich Lab Technology 
Charge-coupled device camera C4880 Hamamatsu 
CO
2
- incubator C200 Labotect 
Consort Electrophoresis Power Supply 800 Sigma-Aldrich 
Cryostat 2800 Frigocut  Reichert-Jung 
Cryostat  Leica 
Histochemistry slides Roth 
High-accuracy weighing machine Bosch 
FACSCanto BD Biosceience 
Micro liter centrifuge Mikro200R Hettich Lab Technology 
Microtome Reichert-Jung 
Microwave  Bosch 
Nalgene Cryo 1°C Freezing Container Nalgene 
Phase contrast inversion microscope CK2 Zeiss 
Photometer Nanodrop PEQLab 
pH-Meter Mettler-Toledo 
Pipettes Abimed 
Pipette-akku, P 900 7001/0294 Hirschmann 
Pipette-standard, P990 30 01  Hirschmann 
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PTC-200 PCR Cycler BioRad 
Stereomicroscope Stemi SV 6 Zeiss 
Table centrifuge 5415D, Thermo mixer Eppendorf 
Transmission electron microscope Zeiss EM 902 Zeiss 
UV-transilluminator Bachmann 
Vortexer L46 GLW 
Water bath TWB 22 Julabo 
  
 
 
2.1.2 Chemicals, enzymes and solutions 
 
Reagent Company 
Acetic acid Merck 
Agarose Biozym 
Amino acids, non-essential  PAA 
Ammonium persulfate Fluka 
BSA (Bovine serum albumin) Sigma-Aldrich 
Cacodylic acid sodium salt trihydrate Merck 
Calcium chloride dihydrate Merck 
Chloroform Sigma-Aldrich 
DAPI (4,6-Diamidino-2-phenylindol)  Roche 
Dulbecco’s modified eagle medium (DMEM)  
(High Glucose) 
PAA 
DMSO (Dimethyl sulfoxide) Sigma-Aldrich 
DNA  ladder Fermentas 
EDTA (Ethylendiamintetraacetic acid) Fluka 
Eosin Sigma-Aldrich 
Entellan mounting medium Merck 
Epon 812  Shell Chemical of Houston 
Ethanol Roth 
Ethidium bromide Sigma-Aldrich 
  Materials and Methods 
 
 
22 
 
Fetal calf serum (FCS)  PAA 
Glutaraldehyde Sigma-Aldrich 
Glycine Merck 
Haematoxylin Sigma-Aldrich 
HEPES buffer Camberex 
L-Glutamine  Sigma-Aldrich 
Methanol  Fluka 
Sodium citrate Merck 
Sodium hydroxide Merck 
Sodium chloride Merck 
PFA (Paraformaldehyde) Sigma-Aldrich 
Penicillin/Streptomycin  PAA 
Phosphate buffered saline (PBS) Lonza 
Propylene oxide Sigma-Aldrich 
RPMI-1640 PAA 
Skim milk powder Roth 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Sodium pyruvate Sigma 
Sucrose Sigma 
Taq- polymarase TaKaRa 
Tissue-Tek O.C.T. Compound  Sakura Finetek Europe 
Tris-base Sigma-Aldrich 
Triton-x-100 Sigma-Aldrich 
Trypan blue  Invitrogene 
Trypsine/EDTA solution Sigma 
Tween-20 Merck 
“VECTASHIELD” mounting medium Vector 
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2.1.3 Drugs and inhibitors 
 
Cimetidine Sigma-Aldrich 
Cisplatin Bristol-Meyers (Platinex) 
Diphenhydramine hydrochloride Sigma-Aldrich 
Disloratadine Sigma-Aldrich 
Famotidine Sigma-Aldrich 
Fluoxetine hydrochloride Sigma-Aldrich 
Ketamine Rotexmedica 
Probenecid Sigma-Aldrich 
Ranitidine hydrochloride Sigma-Aldrich 
Scopolamine N-butyl bromide Sigma-Aldrich 
Quinine Sigma-Aldrich 
Xylizine Loughrea 
 
 
2.1.4 Primers 
 
PCR was performed according to the modified protocol of Nakane et al., 1995. 
XPA: 
XPA-WT:   5’-GTG GGT GCT GGG CTG TCT AA-3’ 
XPA-KO/WT:           5’-ATG GCG TGG GTT CTT CTT C-3’ 
XPA-KO:   5’-ATG GCC GCT TTT CTG GAT TC-3’ 
 
 2.1.5 Antibodies 
 
Rat anti-(Pt-GG) Dr. J. Thomale (Uni Duisburg-
Essen) 
Rabbit anti-(rat OCT1) Alpha Diagnostic International 
(Bio Trend) 
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Rabbit anti-(rat OCT2) Alpha Diagnostic International 
(Bio Trend) 
Rabbit anti-(rat OCT3) Alpha Diagnostic International 
(Bio Trend) 
Rabbit anti-(mouse OCTN1) Alpha Diagnostic International 
(Bio Trend) 
Rabbit anti-(mouse OCTN2) Alpha Diagnostic International 
(Bio Trend) 
Rabbit anti-(mouse OCTN3) Alpha Diagnostic International 
(Bio Trend) 
Rabbit anti-(rat Ig) Cy3    Dianova 
 
Goat anti-(rabbit Ig) Cy3 Dianova 
 
Goat anti-(rat Ig) Alexa Fluor488 
 
Molecular Probes 
 
    
2.1.6 Cell lines 
 
Name Origin Obtained from 
GM 00637 Human skin fibroblasts 
 
Dr. Naegeli,  
University of Zürich 
TKPTS Mouse kidney proximal 
tubule cells 
Dr. Bello-Reuss, 
University of Texas 
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2.1.7 Mouse strains 
 
BALB/c albino House breeding of the 
Institute of Cell Biology, 
University of Essen, 
Germany 
C57BL/6J OlaHsd Wild type 
 
House breeding of the 
Institute of Cell Biology, 
University of Essen, 
Germany 
LSL-K-rasG12D/+ mice onto 
a 129svJae background.   
bearing K-ras mutation House breeding of the 
Koch Institute, MIT, 
Boston 
XPA C57BL/6J, XPA knockout 
 
House breeding of the 
Institute of Cell Biology, 
University of Essen, 
Germany 
 
 
2.1.8 Software 
 
ACAS ICM                  Ahrens Electronics 
Origin 7.0                    Origin Lab Corporation 
FACSdiva                   BD Bioscience 
Bioquant                     Bioquant Image Analysis Corporation 
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2.2 Methods 
 
2.2.1 Breeding and treatment of mice 
 
All animals were kept under specific pathogen free conditions at 12 hours light/dark 
cycle with free access to water and standard laboratory mouse food 
“Zuchthaltungsfutter Maus-Ratte 10 H 10” (Eggersmann) and water ad libitum. 
All experiments have been approved by the state animal welfare board. Mice were 
weighed and checked for signs of drug toxicity before each application of cisplatin. 
Wild type mice. All experiments were performed when animals were aged 12-14 
weeks.  Male C57BL/6J mice (or BALB/c mice for electron microscopy studies) were 
from the in-house breeding stock. All drugs were administrated by i.p. injections and 
treatment regimens were as follows: 10 mg/kg of cisplatin (acute, single treatment) or 
5 mg/kg of cisplatin (plus 500 µl of saline solution) every second day for 8 days 
(cumulative dose: 20 mg/kg of cisplatin; chronic treatment). In the case of inhibitor 
treatment: the inhibitors wer administered 1 hour before cisplatin treatment. In all 
following studies after first check, diphenhydramine (DIPH) was administered 30 
minutes before cisplatin. 
Mice bearing lung tumors. 8 weeks old mice were infected with AdCre (University 
of Iowa) by nasal inhalation as described previously (Jackson et al., 2001; Oliver et 
al., 2010) and were further kept for 12–16 weeks to allow the development of lung 
tumors. 
Treatment of mice was done by i.p. injections in three schedules.  
Acute treatment: 10 mg/kg of cisplatin with or without inhibitor DIPH 57 mg/kg.  
Chronic treatment: 5 mg/kg of cisplatin with or without DIPH plus saline buffer.  
Long-term treatment to study tumor regression: mice were treated onece per week 
with 7 mg/kg of cisplatin, 4 times a month.  
Long term treatment to study drug response of tumors: 4 consecutive treatments 
once per week (7 mg/kg of cisplatin).  
XPA-/- mice.  10 -16 week old males validated by PCR genotyping were used. Mice 
were treated with cisplatin twice (1mg/kg on the first day and 2.5 mg/kg after one 
week). After each cisplatin treatment an i.p. injection of saline (500 µl) was given to 
prevent kidney toxicity. 
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2.2.2 Tissue preparation and frozen tissue section 
 
The sacrificed animals were immediately dissected. Kidneys and lungs were 
submerged in the embedding medium (Tissue-Tek O.C.T. Compound) and frozen in 
liquid nitrogen. Cochleae were dissected and fixed by intralabyrinthine perfusion with 
Carnoy´s solution (3 hours; for DNA adduct staining) or with formaldehyde (4 % in 
PBS; 1 hour; for OCT protein staining). Cochleae were decalcified in EDTA solution 
(10 % w/v in PBS) for 3 days and then placed in sucrose solutions (5 % in PBS for 12 
hours and 15 % in PBS for 5 hours). After that samples were imbedded in special 
freezing blocks with Tissue-Tek medium and were frozen in liquid nitrogen. Frozen 
tissue blocks were stored in sealed freezing vials at -80°C.  
Frozen tissue blocks were placed into the chamber of the cryostat, allowed to 
equilibrate to the chamber temperature (-25°C) for 30 minutes, bound with the 
embedding medium to the specimen block and mounted on the stub. The stub 
temperature was kept at –26°C while cutting. Cryosections (10 µm) from all tissue 
samples were placed onto specific adhesion slides (ImmunoSelect, Squarix Biotech) 
for optimal preservation of structures during the immunostaining procedure. Slides 
were air-dried at 24°C for at least 16 hours and stored at -20°C until further 
processing. 
Carnoy´s fixator:  
60 % Ethanol 
30 % Chloroform 
10 % Acetic acid 
 
2.2.3 Morphological examination of haematoxylin-eosin stained tissue sections 
 
Frozen tissue sections were warmed up to room temperature and fixed in an acetone 
bath at 25°C for 10 minutes. Subsequently the slides were immersed in the 
haematoxylin solution for 5 minutes at 25°C. The slides were then rehydrated for 10 
minutes and stained in 1 % ethanol/eosin solution for 5 minutes. Following washing, 
the slides were dehydrated stepwise in 70 %, in 96 %, and in 100 % ethanol and then 
in xylene by immersing in each solution twice and after that embedded in mounting 
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medium Entellan (Merck). Morphological examination of the samples was performed 
by light microscopy. 
Haematoxyline solution (ingredients were solved in 1000 ml dH2O): 
2 g haematoxyline 
0.2 g NaIO3 
17.6 g KAl(SO4)2 
 
2.2.4 Immunocytological assay (ICA): visualization and measurement of DNA 
adducts 
 
Frozen tissue sections of inner ear or kidneys on the ImmunoSelect slides were fixed 
in methanol at -200C for at least 2 hours or overnight and then rehydrated for 10 
minutes in PBS, at room temperature. To provide better antibody penetration in the 
tissue structures the samples underwent alkaline permeabilisation of cytoplasmic and 
nuclear membranes for 5 minutes at 0°C, followed by washing in PBS at room 
temperature for 5 minutes. The proteolytic cleavage of cytoplasmic and nuclear 
proteins was performed in two steps. At first, pre-warmed pepsin solution (60 µg /ml 
for cell culture or 100 µg/ml for tissue sections in PBS/HCl) was applied onto the 
tissue sections and incubated for 10 minutes at 370C in a humidified chamber. The 
incubation with pepsin was followed by washing in PBS for 10 minutes at room 
temperature. In a second step tissue sections were incubated with pre-warmed 
proteinase K solution (40 µg/ml for cell cultures or 50-100 µg /ml for tissue sections in 
proteinase K buffer) for 10 minutes at 370C in a humidified chamber. Subsequently 
the sections were washed in 0.2 % glycine in PBS for 10 minutes at room 
temperature. Non-specific binding of the antibodies was inhibited by incubation with a 
blocking solution of 1 % casein in PBS for 30 minutes at room temperature. The 
samples were then incubated with a monoclonal antibody (R-C18) specific for Pt-GG 
adducts in DNA (0.1 µg/ml in 0.1 % BSA/PBS) over night at 4°C in the humidified 
chamber. Subsequently, the slides were washed in 0.05 % Tween 20 in PBS for 5 
minutes at room temperature and then in PBS for 5 minutes. The incubation with 
secondary Cy3-labeled rabbit anti-(rat Ig) antibodies, was performed (0.2 µg/ml in 0.1 
% BSA/PBS) for 60 minutes at 37°C in the humidified chamber, followed by washing 
in 0.05 % Tween 20 in PBS for 5 minutes at room temperature and then in PBS for 5 
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minutes. The nuclear DNA was counterstained with DAPI (1 µg/ml in PBS) for 30 
minutes at room temperature. The slides were then washed in PBS. Finally, the 
samples were embedded with a densification compound “VECTASHIELD”. The 
quantification of immuno- and DNA-fluorescence was performed by means of a 
microscope-coupled digital image analysis system ACAS 6.0 Cytometry Analysis 
System. Adduct levels in the nuclear DNA of individual cells were calculated by 
normalizing antibody-derived fluorescence signals to the corresponding DNA content 
of the same nucleus, and were expressed as arbitrary fluorescence units (AFUs). 
Data were assigned to specific cell types as determined by histochemistry.  
 
Solutions for ICA: 
Alkali solution: 
60 % 70 mM NaOH / 140 mM NaCl,  
40 % methanol 
Proteinase K-Buffer:  
20 mM Tris 
2 mM CaCl2, pH 7.5 
Glycin/PBS:  
 0.2 % Glycin in PBS 
PBST: 
0.05 % Tween 20 in PBS 
 
2.2.5 Immunohistochemistry on frozen sections: visualization of OCT proteins 
 
Slides with tissue sections were left at room temperature for 10 minutes and then 
fixed in pre-cooled ethanol at -20°C for 30 minutes. Subsequently, samples were 
washed three times in PBS for 5 minutes. Slides were then blocked in skim milk 
solution for 30 minutes. Immunohistochemical staining was accomplished with 
antibodies that recognize the target protein. First rabbit anti-(OCT) antibodies (OCT1-
3 or OCTN 1-3; 0.5 µg/ml in 1m% BSA/PBS) were applied on slides and incubated in 
a humidified chamber at room temperature for 90 minutes. After that samples were 
washed three times in 0.1 % BSA/PBS. Secondary antibodies (0.2 µg/ml) were 
applied on the slides and incubated for 45 minutes at room temperature. Samples 
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were washed three times in 0.1 % BSA/PBS at room temperature. Counterstaining of 
DNA was performed with DAPI (1 µg/ml in PBS) for 30 minutes at room temperature. 
Slides were washed in PBS for 5 minutes and covered with “VECTASHIELD” 
mounting medium. Visualization of the protein localization was performed with a 
Zeiss Axioplan fluorescence microscope and documented with a charge-coupled 
device camera C4880. 
 
2.2.6 Electrophysiological examination of the hearing capability of mice: 
auditory brainstem response evaluation 
 
Auditory brainstem response or brainstem auditory evoked response (BAER) is an 
electrical signal evoked from the brainstem by the presentation of a sound such as a 
click. BAER is a clinical screening test to monitor for hearing loss or deafness 
assessing the functions of the ears, cranial nerves, and various brain functions of the 
lower part of the auditory system. 
The cochlea acts as a mechanical demodulator in the hearing process and is 
responsible for converting sound vibrations into nerve impulses (Johnstone and 
Sellick, 1972). The stimulation of associated nerve endings and conduction signal 
through afferent nerves via the cochlear ganglia to the cochlear nucleus, then to the 
superior olivary complex, then to the inferior colliculus, then to the medial geniculate 
body and finally to the auditory cortex (Fig. 9). 
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Fig. 9: The waveform of a normal brainstem auditory evoked response. Wave I represents the 
electrical potential from outer hair cell stimulation. Waves II, III, and IV derive from cochlear nucleus, 
superior olivary complex and lateral lemniscus potentials, respectively. Wave V is the response from 
the middle brain – inferor colliculus – which is measured by BAER to determine the level of hearing 
performance. (Figure adopted from Lippincott Williams & Wilkins Products). 
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All electrophysiological examinations were carried out under general anesthesia 
(xylazine, 20 mg/kg, plus ketamine, 100 mg/kg; i.p.). To minimize effects of body 
temperature on the evaluation process, animals were placed to a heated (37°C) 
thermal blanket.  
Subdermal needle electrodes were inserted at vertex (active electrode), ventrolateral 
of left pinna (reference electrode) and ventrolateral of right pinna (ground electrode) 
(see Fig. 25). For acoustic stimulus presentation, auditory brainstem response 
recording and data management a modified clinical potential system (NeuroScreen 
Plus, Toennies, Germany) was used. Repetitive clicks (substantial energy: 1-3 kHz; 
duration: 10 ms, rate: 39 /s) were delivered through plastic tubes (diameter: 3 mm) to 
both ear canals (EAR-Auditory Systems, Indianapolis). BAER thresholds were 
determined by clicks beginning at 90 dB sound pressure level with decreasing 
intensity (10 dB-steps) until the waves have lost reproducible morphology. The BAER 
thresholds were determined separately for each ear and by repetitive measurements. 
Following BAER, mice were sacrificed by cervical dislocation and both cochleae were 
removed for ICA analysis. 
 
2.2.7 Electron microscopy examination 
 
C57BL/6J mice and BALB/c mice were used untreated or treated chronically with 
cisplatin (see 2.2.1). Dissected cochleae and pieces of kidney cortexes were fixed in 
2.5% glutaraldehyde in cacodylat buffer (0.1M, pH = 7.4). The cochleae were 
decalcifyed in 10 % EDTA for 3 days. The samples were rinsed in several changes of 
phosphate buffer and fixed in 1 % osmium tetroxide for 3 hours with subsequent 
washing in PBS. Following dehydration through a graded series of ethanol, the 
tissues were washed with propylene oxide and immersed in a mixture of propylene 
oxide and Epon 812 (25:75 for 1 hour, 50:50 for 1 hour, 75:25 for 1 hour) and then 
Epon 812 pure over night. The next day samples were embedded in Epon 812 and 
left for 36 hours at 60°C for polymerization.  
Ultrathin sections (90 nm) were taken from selected areas and mounted on grids. To 
increase structural contrast for electron microscopy, sections were counterstained 
with uranyl acetate and lead citrate (1:1). Tissue observation and photographic 
documentation were made with a transmission electron microscope Zeiss EM 902.  
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2.2.8 Annexin V apoptosis detection 
 
Staining with FITC-labeled Annexin V was used to determine the percentage of cells 
within a population that are actively undergoing apoptosis. The method is based on 
the changes due to early stages of apoptosis: loosing membrane asymmetry due to 
the membrane phospholipid phosphatidyl serine (PS) that is translocated from the 
inner leaflet of the plasma membrane to the outer leaflet. After translocation, PS 
becomes exposed to the external environment. Annexin V is a calcium-dependent 
phospholipid-binding protein that has a high affinity for PS, and is used for identifying 
apoptotic cells with externally exposed PS (Fig. 10). Propidium iodide (PI) was used 
to distinguish viable from nonviable cells in flow cytometry as a standard test of cell 
viability. Living cells with intact membranes exclude PI whereas the membranes of 
dead or damaged cells are permeable to PI. Cells that stain positive for Annexin V 
and negative for PI are undergoing apoptosis. Cells that stain positive for both 
Annexin V and PI are either in the end stage of apoptosis, are undergoing necrosis, 
or are already dead. Cells that stain negative for both, Annexin V and PI, are alive 
and are not in the process of apoptosis. 
Cells were cultivated in RPMI 1640 or DMEM medium with 10 % FCS in a humidified 
atmosphere containing 5% CO2. After reaching 60 % confluence cells were treated 
with cisplatin alone (5 or 10 μg/ml), or in combination with DIPH (100 μg/ml), or with 
DIPH alone. 
After 24 hours, cells were trypsinized, washed twice with PBS, and resuspended in 
100 μl of Annexin–binding buffer (Annexin V-FITC Apoptosis Detection Kit I from BD). 
Cells were then stained with 5 µl of Annexin V-FITC and with 5 µl of PI for 15 
minutes. Finally, 400 µl of Annexin-binding-buffer was added and cells were analysed 
by flow cytometry (FACScanto, BD) and evaluated with FACSdiva software. 
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Fig. 10: Schematic scheme of apoptosis-induced membrane changes recognized by Annexin V. 
During early apoptosis, the plasma membrane loses asymmetry causing phosphatidylserine to be 
translocated from the cytoplasmic face of the plasma membrane to the external face which can be 
detected using Annexin V. (Figure adopted from R&D Systems). 
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3. Results 
 
3.1 Establishing a mouse model for cisplatin–induced ototoxicity 
 
The cellular and molecular mechanisms underlying the organ-specific toxicity of 
cisplatin in the inner ear and in the kidney have been studied predominantly in 
mammalian cell culture systems employing immortalized physiological cells such as 
proximal tubule cell lines. The majority of these studies were unable to explain the 
particular sensitivity of the target tissues to cisplatin because the cell systems 
resembled neither the complex pharmacokinetic situation within the affected organs 
nor the particular response of terminally differentiated, non dividing cells to the drug. 
It is widely accepted that the cells of the kidney which are damaged predominantly 
during cisplatin treatment, and, are responsible for the nephrotoxicity and general 
renal dysfunction, are the epithelium cells of the proximal tubules (Arany and 
Safirstein, 2003). This had been evidenced by morphological studies in patients and 
animals treated with cispatin as well as by comparisons of various kidney cell lines 
developed from different cell types. The inner ear damage after cisplatin treatment 
was detected mainly by electron microscopic analysis but also by morphological 
studies of the cochlea (Klis et al., 2002; Cardinaal et al., 2004; Rybak and 
Ramkumar, 2007; Laurell et al., 2007). The main conclusions from the 
aforementioned studies were that: (1) cisplatin-treated animals lost their cochlear hair 
cells, (2) the damage of the cochlea by cisplatin begins from the basal turn, (3) 
cisplatin causes degeneration of the stria vascularis and the spiral ganglion neurons. 
It has to be mentioned that almost all animal studies on the inner ear have been done 
so far with rats or guinea pigs, as cochleae of these animals are large enough to 
allow easy handling. The conclusions drawn from these studies neither provided 
clear evidence, how to design preventive treatment strategies, nor did they help to 
identify the primary molecular targets of cisplatin-ototoxicity and discriminate them 
from secondary effects. As no suitable transgenic rat or guinea pig strains for more 
detailed studies were available we first have established a mouse model to analyze 
the parameters targeting the toxicity of cisplatin to specific structures within the inner 
ear and the kidney. 
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3.1.1 Cochlea and kidney harbor specific target cells for cisplatin 
 
According to our hypothesis that cisplatin mediates its toxic side effects in 
physiological cells also via the formation of cisplatin-DNA adducts the concentration 
and distribution of adducts was determined in different cell types of the inner ear and 
the kidney of drug-treated mice. For this purpose, male C57BL/6J mice (age 12 
weeks) were injected i.p. with a single dose of cisplatin (10 mg/kg). Twenty four hours 
later, the inner ears and kidneys were dissected, kidneys were frozen immediately 
and cochleae were fixed and decalcified. Cryosections (10 µm) prepared from the 
tissues were placed onto specific adhesion slides.  Slides were then immunostained 
for the visualization of platinum-guanine-guanine (Pt-GG) intrastrand adducts in the 
nuclei of individual cells by using the adduct-specific monoclonal antibody R-C18 in 
an immunocytological assay (ICA) developed in our lab (Liedert et al., 2006). The 
tissue sections were then stained with a secondary Cy3-labeled goat-anti-rat 
antibody (red), counterstained with DAPI (blue) for nuclear DNA, and analyzed in the 
fluorescence microscope (Fig. 11). Serial sections from the same tissues were 
stained for morphological orientation with hematoxyline and eosin (H&E).  
This analysis revealed a drastically unequal distribution of the nuclear DNA 
platination among cochlear cells. Two particular areas, parts of the organ of Corti and 
cells of the stria vascularis depicted extremely high levels of Pt-GG adducts whereas 
other structures were stained to a far lower degree (Fig. 11 A). A similar observation 
was made for kidney tissues, where the DNA of proximal tubular cells carried very 
high adduct burdens, whereas other types of cells depicted much lower levels of DNA 
platination (Fig. 11 B). 
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Fig. 11: High accumulation of platinum adducts in the DNA of particular cell types in the kidney 
and the cochlea of cisplatin-treated mice. 24 h after a single dose of cisplatin (10 mg/kg) Pt-GG 
intrastrand crosslinks in DNA were visualized by immunostaining of frozen sections with the adduct-
specific antibody R-C18 (red) and counterstaining of the nuclear DNA with DAPI (blue). For 
morphological orientation serial sections of both organs were stained with hematoxyline and eosin 
(H&E; upper left micrographs). (A) Cochlea with high adduct levels in marginal cells (MC) in the stria 
vascularis (SV) and hair cells (HC) in the organ of Corti (OC). (B) Kidney with high adducts levels in 
proximal tubule cells (PTC). Magnification: 20x. 
 
Micrographs of the organ of Corti at higher magnification (60x) clearly demonstrated 
high levels of DNA platination exclusively in the outer hair cells (OHC) but not in inner 
hair cells (IHC) or other cell types of organ of Corti (Fig.12 A). This observation is in 
line with structural damage in OHCs as seen in electron microscopy studies in 
cochleae from cisplatin treated rats (Hamers et al., 2003).  
More detailed analysis of the stria vascularis revealed a similar situation. High adduct 
levels were visible in this structure only in the outer cell layer representing the 
marginal cells, but not in the neighboring intermediate or basal cells (Fig. 12 B). 
 
 
 
 
 
 
 
 
  Results 
 
 
39 
   
A
 
 
B 
 
 
 Fig. 12: Localization of Pt-GG adducts in cells of the inner ear. 24 h after a single dose of 
cisplatin (10 mg/kg) Pt-GG intrastrand crosslinks in DNA were visualized by immunostaining of frozen 
sections with the adduct-specific antibody (red) and counterstaining of the nuclear DNA with DAPI 
(blue). (A) Organ of Corti. Left: the nuclear DNA of the three outer hair cells is massively platinated 
(Magnification 60x). Right: schematic drawing of the organ of Corti with outer (OHC) and inner hair 
cells (IHC) (picture from Oxford Illustrated Science Encyclopedia, modified). (B) Detailed view of the 
stria vascularis. Left: stria vascularis with highly platinated marginal cells (magnification: 60x). Right: 
schematic drawing of the stria vascularis with localization of marginal, intermediate and basal cells and 
fibrocytes of the spiral ligament (Jentsch, 2000). 
 
  Results 
 
 
40 
   
 
 
3.1.2 Quantification of Pt-GG adducts in the nuclei of cochlear cells 
 
For the numerical determination of the DNA platination levels in the nuclei of 
individual cells, a Zeiss Axioplan fluorescence microscope coupled to a quantitative 
multichannel digital image analysis system (ACAS 2) was applied. This system 
automatically localizes single nucleus areas due to the DAPI-derived signals from 
DNA and integrates the intensities of the antibody-derived Cy3 signals for the same 
pixels (Liedert et al., 2006). Relative adduct levels in the nuclear DNA of individual 
cells were calculated by normalizing antibody-derived fluorescence signals to the 
corresponding DNA content of the same cell (in order to correct for a possible DNA 
loss) and were expressed as arbitrary fluorescence  units (AFUs). The AFU values 
were used as quantitative parameters and mean values (± SD) from 50 or 100 cells 
from the organ of Corti or the stria vascularis, respectively, were calculated to 
describe the relative adduct levels in particular cell types. 
Mice were i.p. injected with 10 mg/kg of cisplatin and euthanized after 24 h or 48 h. 
Cryosections of cochlea and kidney tissues were stained with anti Pt-GG antibody 
and signals were measured from single nuclei of different types of cells. When 
analyzing the immunostained cochlea sections, four types of cells were measured 
separately: (1) outer hair cells, (2) surrounding cells (supporting cells of the organ of 
Corti), (3) marginal cells of the stria vascularis and (4) adjacent cells (intermediate 
and basal cells of the stria vascularis) (Fig. 13).  
The levels of Pt-GG adducts in the highly platinated cells and directly neighboring 
cells of the cochlea were dramatically different being 11-fold higher in OHC vs. 
adjacent cells in the organ of Corti (13.26 AFUs vs. 1.19 AFUs), and 5-fold higher in 
the marginal cells as compared to the other cell types in the stria vascularis (9,85 
AFUs vs. 2.08 AFUs).  
In the kidney, proximal tubule cells, distal tubule cells and cells of the glomerulus 
were measured in the same way. The platination level in distal tubular cells was twice 
as high as that in glomerulus cells (2.61 AFUs vs. 0.97 AFUs) whereas the proximal 
tubular cells showed the highest level of platination (7-fold higher than distal tubular 
cells: (18.97 AFUs vs. 2.61 AFUs). 
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Fig. 13: Accumulation of platinum-DNA adducts in different cell types of the cochlea and the 
kidney cortex 24 h after cisplatin treatment. (A) Relative levels of Pt-GG adducts in outer hair cells 
(HC) and in marginal cells (MC) as compared to surrounding cells (SC). (B) Distribution of Pt-GG 
adducts in the kidney cortex: Comparison between cells of the proximal or distal tubules and cells of 
the glomeruli. The columns represent mean values (+/- SD) from 100 measured cells (for HC from 50 
cells). 
 
 
3.1.3 Different adduct levels in basal, middle and apical turns of the cochlea 
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A number of previous reports had described differences in the extent of 
morphological damage between basal and apical turns of the cochlea in the stria 
vascularis marginal cells of cisplatin-treated rats (Cardinaal et al., 2004; van Ruijven 
et al., 2005; Laurell et al., 2007). To test whether such observations are correlated to 
differences in DNA platination, ICA analyses were performed with cryosections from 
all four turns of the cochlea from a mouse 24 h after cisplatin treatment. The 
quantitative measurement supported the structural observations by showing a 
decrease in marginal cell adduct levels from the basal to the apical turn (Fig. 14). A 
similar trend, although at nearly 10-fold lower levels, was also observed for the non-
marginal cells of the stria vascularis. This finding corresponds to the clinical 
observations that cisplatin-induced hearing loss begins with high frequencies, which 
are recorded predominantly in the basal turn of the cochlea (Sluyter, 2003; Rybak 
and Ramkumar, 2007). The pharmacokinetic background for the unequal distribution 
of platinum-DNA adducts between upper and lower turns of the cochlea are not 
known. 
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Fig. 14: Levels of Pt-GG adducts in cells of the stria vascularis from different turns of the 
cochlea. Cochleae were dissected from mice 24 h after a single dose of cisplatin (10 mg/kg) and 
serial cryosections were measured for DNA adduct levels in different cell types by ICA analysis. AFU 
values were significantly higher in marginal cells (MC) of the basal turn as compared to the apical turn. 
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A similar tendency was found for other cells of the stria vascularis (SC: intermediate and basal cells), 
however, on a 10-fold lower level of DNA platination. 
 
 
3.2 The exploration of mechanisms underlying the excessive DNA platination in 
hair, marginal and proximal tubule cells 
 
The dramatic accumulation of platinum adducts in particular cell types in the cochlea 
and the kidney of cisplatin-treated mice raised the question of the mechanisms 
underlying that observation. Basically, all the functions discussed for drug 
susceptibility of tumor cells (i.e. accelerated cellular uptake or decreased export of 
the drug, abrogation of the intracellular deactivation, or the incapability to repair 
adducts once formed in the DNA) might also be involved in physiological cells, and 
could all lead to the observed differential accumulation of platinum adducts.  
 
3.2.1 Formation and repair of Pt-GG adducts in the DNA of different inner ear 
cells 
 
It had been shown that Pt-GG intrastrand cross links can be removed efficiently from 
the nuclear DNA of cells in various mouse tissues by the nucleotide excision repair 
pathway (Dzagnidze et al., 2007). Therefore, it was first analyzed whether a 
deficiency in DNA repair might be responsible for the high adduct accumulation in 
OHCs or marginal cells of the cochlea. C57BL/6 mice were treated with a single dose 
of cisplatin (12.5 mg/kg) and three animals were sacrificed at each of the different 
time points (2, 16, 48 and 72 h) after injection. Adduct levels were measured by ICA 
in three cell types of the cochlea, namely outer hair cells, marginal cells and cells of 
Reissner’s membrane (Fig. 15). The latter only showed weak immunofluorescence 
signals at all time points after cisplatin treatment, and were chosen as an example for 
low adducted cochlear cells. The OHCs and the marginal cells depicted high levels of 
adduct formation after cisplatin treatment and were designated as target cells. 
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Fig. 15: Kinetics of Pt-GG adduct formation and repair in different cell types of the cochlea. 
Mice were treated with a single dose of cisplatin (12.5 mg/kg; i.p.) and were sacrificed at different time 
points. DNA adduct levels in outer hair cells (HC), in marginal cells (MC) and in cells of Reissner’s 
membrane (RM) were measured by ICA analysis The data represent mean values (+/- SD) of >50 
individual nuclei per cell type and from 2 independent experiments.  
 
DNA platination was detectible in all three cell types already 2 hours after cisplatin 
administration (Fig. 15). The Pt-GG levels peaked after 16 hours in OHCs and after 
48 hours in marginal and RM cells. They returned to comparatively low values in all 
three cell types 72 hours after treatment. As expected from the previous experiments, 
the adduct levels of the RM cells were only about 10 % of those of the two other cell 
types. The repair kinetics, however, clearly demonstrated that the excessive DNA 
platination in both OHC and marginal cells is not caused by their inability to repair 
such lesions. 
This observation strongly implied that factors other than repair deficiency are 
responsible for the exorbitant DNA damage in the two target cell types. As mentioned 
above, proximal tubule cells of the kidney have physiological similarities with cochlear 
hair and marginal cells, namely their capacity of intensive unidirectional ion transport. 
Thus, in the next step we aimed to identify membrane transporters which are 
expressed in the highly adducted cells in the kidney and in the inner ear, but not in 
the surrounding cells, as a possible cause for an aberrant active uptake of cisplatin.  
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3.2.2 Localization of organic cation transporters in the cochlea 
 
Based on experiments with cell culture systems, various types of membrane 
transporters have been suggested to be involved in the import and export of cisplatin, 
thereby modulating the cellular sensitivity to the drug (Ishida et al., 2002; Samimi et 
al., 2003; Yonesawa et al., 2005; Burger et al., 2010). One of these transporters is 
the organic cation transporter 2 (OCT2), which is highly expressed in the kidney 
cortex and is assumed to represent a specific marker for proximal tubule cells 
(Ciarimboli et al., 2005). Therefore, it was tried to localize OCT2 and other members 
of the same transporter family in the murine inner ear. For this, cochleae were 
dissected from untreated 12-weeks old male C57BL/6 mice, fixed, and decalcified as 
described in Material and Methods (see 2.2.2). Eight micron thick tissue sections 
were prepared and immunostained for six different members of the OCT family, 
namely for OCT1, OCT2, OCT3, OCTN1, OCTN2 and OCTN3, using specific 
antibodies. No signals were detectable after staining for OCT1, OCTN1 or OCTN3 
(data not shown). In contrast, OCT2 and OCT3 were positively stained in 
intermediate and basal cells of the stria vascularis, in supporting cells of the organ of 
Corti (cells surrounding the outer hair cells) and even in inner hair cells (Fig. 16). 
However, no signals were visible in the actual target cells of cisplatin, the marginal 
cells and the outer hair cells. From these findings it can be concluded that none of 
the six OCT family members tested here, is likely to be responsible for an aberrant 
import of cisplatin into the critical target cells. 
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Fig. 16: Immunohistochemical localization of organic cation transporters in the organ of Corti 
and the stria vascularis of the cochlea. Cryosections of formalin-fixed cochleae were 
immunostained (red) with antibodies for the membrane transporters OCT2 (A, B) and OCT3 (C, D), 
and were counterstained for DNA with DAPI (blue). Arrows indicate the position of the outer hair cells 
in the organ of Corti. B and D :Cells of the stria vascularis with OCT2 and OCT3 located in the area of 
the intermediate cells. (Magnification: A: 60x; B, C, D: 40x). 
 
 
 
3.3 Augmented levels of platinum-DNA adducts in cochlear cells of NER-
deficient mice correlate with a higher degree of hearing loss 
 
It is generally accepted that the antineoplastic effect of platinum anticancer drugs is 
mediated via the formation of adducts in the nuclear DNA of tumor cells and the 
subsequent induction of apoptotic pathways. For drug-induced damage and 
functional loss in physiological cells, however, this route of action is by far less well 
established and a matter of constant controversial discussion in the literature. The 
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neurotoxic effect of cisplatin was correlated to structural damage of the mitochondria 
in neurons and satellite cells of the dorsal root ganglia (Bottone et al., 2008; 
Cavaletti, 2008). To investigate whether the accumulation of DNA platination 
products are really causing the ototoxicity in our in vivo model, two isogenic mouse 
strains (C57BL/6 NER wild type and XPA -/-) were compared which differ solely in 
their ability to repair cisplatin intrastrand adducts in their genomic DNA. While the 
wild type mice have a fully functional NER system, a homozygous deficiency for the 
xeroderma pigmentosum (XP) A protein, a major component of the NER pathway, 
has been shown to reduce (but not to completely abrogate) the repair capacity for Pt-
GG intrastrand cross links in the DNA of various tissues (Liedert et al., 2006; 
Dzagnidze et al., 2007). 
 
3.3.1 Increased cisplatin ototoxicity in XPA knockout mice 
 
As a functional test for the hearing capability of mice we employed the method of 
brainstem auditory evoked response (BAER). This assay is based on the 
measurement of neurosensorial responses in the central auditory pathways of the 
brainstem after scaled acoustic stimulation by a sound generator. For this, mice were 
deeply anesthetized and electrodes were placed on the scalp and on each earlobe. A 
clicking sound was delivered via small earphones and the evoked waves of neuron 
activity were recorded. 
XPA -/- mice and their wild type littermates were treated with cisplatin at a low 
cumulative dose of 3.5 mg/kg within two weeks (1st week: 1 mg/kg; 2nd week: 2.5 
mg/kg). Control groups of both strains received PBS injections instead. The hearing 
capability of animals in all four experimental groups was determined by BAER 
measurement 48 hours after the last treatment. The treated and the control groups of 
the repair-proficient mice did not exhibit any sign of cisplatin ototoxicity (Fig. 17 A). 
The control group of the repair-deficient XPA-/- mice exhibited the same hearing 
threshold, indicating that the status of the NER system itself did not result in any 
hearing problems. In contrast, cisplatin treated NER-deficient XPA-/- mice exhibited a 
reduction of their hearing capability of nearly 50 %, indicating that unrepaired DNA 
adducts may indeed represent the initial molecular trigger for the functional hearing 
loss. 
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3.3.2 Higher accumulation of DNA adducts in cochlear cells of XPA-deficient 
mice 
 
To further substantiate this indication, the mice of all four experimental groups were 
sacrificed immediately after the BAER test and cochleae were taken for adduct-
specific immunostaining with anti-Pt-GG monoclonal antibodies. The ICA revealed 
about 2.7-fold higher levels of DNA damage in the marginal cells of cisplatin-treated 
XPA-/- mice compared to their wild type littermates (Fig. 17 B). Thus, the platinum 
adduct levels correlated well with the functional loss in the hearing system. 
 
3.4 A strategy for the prevention of cisplatin-induced hearing loss 
 
Having demonstrated the role of unrepaired cisplatin-DNA damage in hearing loss 
and its excessive formation rates in target cells of the affected tissues, the next 
logical step was to investigate preventive strategies for the severe side effects of 
cisplatin treatment, such as ototoxicity. Assuming that aberrant import of the drug by 
physiological membrane transporters gives rise to the high DNA platination in 
marginal and outer hair cells, the obvious strategy was to prevent the damage by 
trying to transiently block those transporters. As the molecular characterization of the 
responsible membrane pump by in situ immunostaining was not obvious, a functional 
in vivo screening was performed in the mouse model as an alternative strategy for 
the identification of possible pharmacological inhibitors. 
 
 
  Results 
 
 
49 
   
control cisplatin control cisplatin
0
20
40
60
80
100
H
ea
rin
g 
ca
pa
ci
ty
, %
control cisplatin control cisplatin
0
1
2
3
4
5
Pt
-G
G
 in
 D
N
A
 (A
FU
s)
 
 
Fig. 17: Mice with reduced DNA repair capacity are more prone to cisplatin-induced ototoxicity 
and accumulate higher levels of Pt-GG adducts in the DNA of cochlear target cells. C57BL/6 
(wild type) mice and syngenic DNA repair-deficient (XPA-/-) mice were repetitively treated with low 
doses of cisplatin (cumulated dose: 3.5 mg/kg) and the hearing capability was measured 24 h after the 
last dose by the BAER test in comparison to untreated controls. (A) The columns represent means (+/- 
SD) of three consecutive measurements per animal and of 5 mice per treatment group. The hearing 
capability was significantly reduced by 45 % in the group of cisplatin-treated XPA-/- mice whereas no 
effects were observed in untreated XPA-/- mice or in wild type mice after cisplatin exposure. (B) Levels 
of accumulated DNA adducts in the inner ear. All mice in the experiment were sacrificed immediately 
after the BAER test and cryosections of cochlea were analyzed for Pt-GG adduct levels by ICA 
analysis. After equal doses of cisplatin, inner ear cisplatin target cells of XPA -/- mice depicted more 
than 3 times higher adduct levels than those of the wild type littermates. * indicates P ≤ 0.001 vs. wild-
type.                        
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3.4.1 Screening for cisplatin uptake inhibitors 
 
According to reports on cisplatin transporters in various cell lines (Ciarimboli et al., 
2005; Müller et al., 2005) a group of nine small molecules was chosen as candidate 
compounds for an in vivo screening for cisplatin uptake inhibitors (Fig. 18). Among 
them was cimetidine as a well known inhibitor of the OCT2 cation transporter. In a 
first set of experiments, four compounds were tested, namely quinine, 
butylscopolamine, diphenhydramine and ranitidine. The mice were separated into two 
groups for pretreatment with low or high doses of the test compounds. One hour 
before the treatment with cisplatin (10 mg/kg) the high dose group received i.p. 
injections of either quinine (100 mg/kg), ranitidine (100 mg/kg), diphenhydramine (60 
mg/kg) or butylscopolamine (20 mg/kg). The low dose group received half the dose of 
the high dose group (50, 50, 30 or 10 mg/kg, respectively). As controls, two mice 
were treated with PBS instead of inhibitor prior to cisplatin (positive control) and two 
mice were treated with PBS only (negative control). All mice were sacrificed 24 hours 
after cisplatin treatment. Cochleae and kidneys were dissected for immunostaining 
and ICA analyses of Pt-GG adduct levels in specific cell types (Fig. 19). 
In tissue sections from mice pretreated with quinine or butylscopolamine no inhibition 
of DNA platination was observed, independent of the dosing, in either of the three 
target cell types (renal tubulus epithelium cells, cochlear marginal and outer hair 
cells). In contrast, high dose treatment with ranitidine had a slightly protective effect 
(15 – 20 % reduction of adduct levels) in all three cell types, whereas the lower dose 
provided no protection. Pretreating the mice with diphenhydramine provided a dose-
dependent and by far the strongest shielding from DNA damage, ranging from 75 % 
in proximal tubule cells over 70 % in cochlear marginal cells to about 50 % in outer 
hair cells at the high dose of 60 mg/kg (Fig. 19). No significant inhibition by any of the 
four inhibitors was observed in the low-adduct “non-target” cells of Reissner’s 
membrane of the cochlea (Fig. 19). 
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Fig. 18: Small molecules investigated for their applicability as import inhibitors for cisplatin in 
vivo.  
 
Having identified diphenhydramine (DIPH) as a potent pharmacological inhibitor of 
the excessive DNA platination in critical renal and cochlear cells, it was of interest to 
pinpoint the specific functions that might be affected by the compound. DIPH has 
been shown to have a rather broad spectrum of physiological effects (Garnett, 1986; 
Harris, 2008). Therefore, we intended to use a panel of other small molecules which 
might mimic specific effects of DIPH in our mouse model. In the first instance, DIPH 
was characterized for its antihistaminic activity by blocking the pertinent H2 
receptors. Therefore, we tested two other H2 receptor antagonists, cimetidine and 
famotidine, in addition to ranitidine (Fig. 18 and 20), as well as desloratadine as a 
highly specific H1 antagonist. Furthermore, we included cimetidine and famoditine 
because of their known activity as OCT2 inhibitors, fluoxetine as a serotonin re-
uptake inhibitor, and butylscopolamine, which was described to be an anticholinergic 
agent and a muscarinic receptor antagonist. All these functions have also been 
associated with the pharmacologic activity of DIPH. Finally, probenecid was included 
in these experiments as a presumed inhibitor of members of the organic anion 
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transporter (OAT) family. All these compounds were applied separately to two mice at 
concentrations representing half of the LD50 dose one hour before cisplatin 
treatment. Mice were sacrificed 24 hours after cisplatin treatment and adduct levels in 
cochleae and kidneys were determined as above. No significant inhibitory effects on 
the DNA platination in the target cells were detected for any of the compounds (Fig. 
20). 
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Fig. 19:  Accumulation of the Pt-GG adducts in cells of the kidney and the inner ear of cisplatin-
treated mice with co-administration of transport inhibitors.  Potential inhibitors were i.p.-injected 
at two different doses 1 h before cisplatin treatment (10 mg/kg). Mice were sacrificed 24 h after 
cisplatin treatment and Pt-GG adducts were measured in the DNA of target and non-target cells by 
ICA analysis. (A) Proximal tubule cells of the kidney. (B) Outer hair cells of the cochlea. (C) Stria 
vascularis marginal cells of the cochlea. (D) Cells of Reissner’s membrane. (+): cisplatin; ( - ): PBS 
treated control; R: Ranitidine, D: Diphenhydramine; Q: Quinine; B: Butylscopolamine; h: high dose; l: 
low dose.  
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Fig. 20: Accumulation of the Pt-GG adducts in cells of kidney and inner ear of cisplatin-treated 
mice with co-administration of transport inhibitors. Potential inhibitors were i.p.-injected at the 
maximum tolerated dose 1 h before cisplatin treatment (10 mg/kg). Mice were sacrificed 24 h after 
cisplatin treatment and Pt-GG adducts were measured in the DNA of target and non-target cells by 
ICA analysis. (A) Proximal tubule cells of the kidney. (B) Outer hair cells of the cochlea. (C) Stria 
vascularis marginal cells of the cochlea. (D) Cells of Reissner’s membrane. (+): cisplatin; (-): PBS-
treated control; F: Famotidine (20 mg/kg); P: Probenecis (150 mg/kg); C: Cimetidine (15 mg/kg); Fl: 
Fluoxetine (30 mg/kg); Ds: Desloratadine (240 mg/kg, oral). For none of the compounds a significant 
reduction in DNA adduct levels was observed in comparison to the cisplatin alone treatment. 
 
 
 
3.4.2 DIPH reduces the DNA platination in cochlear marginal cells and in kidney 
cortex cells in a dose-dependent manner  
 
In the first set of experiments the applied doses of DIPH to reduce the adduct 
formation in the target cells were corresponding to 50 % and 25 % of the LD50 dose 
for mice. Therefore, it was tested next whether the inhibitory effect of DIPH is dose-
dependent and whether it is possible to reduce the dose while maintaining the 
preventive activity on adduct formation. For this, mice were pre-treated by i.p. 
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injections with DIPH at different doses between 0 and 57 mg/kg (two mice per group) 
30 minutes prior to a single dose of cisplatin (10 mg/kg). The ICA for Pt-GG adducts 
in kidney and cochlear cells revealed a dose-dependent inhibition of the adduct 
accumulation in proximal tubule cells and in marginal cells (Fig. 21). No significant 
alterations were observed in the low-platinated distal tubule cells of the kidney and in 
the basal and intermediate cells of the stria vascularis. This shows that the inhibitor 
has a specific effect on proximal tubule cells and marginal cells but has no effect on 
the surrounding cells (such as distal tubule cells; Fig. 21 B). 
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Fig. 21: Dose-dependent effect of DIPH on adducts accumulation in different cell types. Mice 
were treated with cisplatin alone (0) or in combination with different doses of DIPH (5, 15, 30, 57 
mg/kg), sacrificed 24 h later and the DNA adduct levels were measured in kidney and cochlear cells by 
ICA analysis. (A) Marginal cells of the inner ear (green squares). (B) Proximal (blue squares) and 
distal tubules (black circles) of the kidney.  
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3.4.3 No interference of DIPH with the repair capacity for cisplatin-DNA adducts 
in cochlear target cells  
 
As shown above the pre-treatment with DIPH prior to cisplatin injections leads to 
lower levels of DNA adduct accumulation in the target cells. This could be caused by 
reduced intracellular drug concentrations, or alternatively, by augmented removal of 
those lesions from the genomic DNA of the target cells. To elucidate a possible 
interaction of DIPH with the DNA repair machinery, we functionally analyzed its 
efficiency by measuring adduct kinetics. Mice were pretreated with DIPH (57 mg/kg) 
and 30 minutes later with a single dose of cisplatin (12.5 mg/kg). Three mice per time 
point were sacrificed at 2, 16, 48 and 72 hours after cisplatin treatment and cochleae 
were measured for Pt-GG adduct levels by ICA (Fig. 22). The kinetics revealed 
drastically decreased DNA platination in marginal and outer ear cells in DIPH pre-
treated animals as compared to the corresponding cisplatin alone group at all time 
points, but no obvious differences in their capability to repair the damage.  
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Fig. 22: Influence of DIPH co-application on the formation and repair kinetics of Pt-GG adducts 
in the DNA of different cochlear cell types of cisplatin-treated mice Animals were pre-treated or 
not with DIPH (57 mg/kg) and were i.p. injected 30 minutes later with cisplatin (12.5 mg/kg). Each two 
mice were sacrificed at 2, 16, 48, or 72 hours after cisplatin and Pt-GG adduct levels in the DNA of 
inner ear cells were determined by ICA analysis. (A) With DIPH. (B) Without DIPH. HC: outer hair 
cells; MC: marginal cells; RM: cells of Reissner’s membrane. 
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3.4.4 DIPH does not lead to reduced DNA damage in vitro 
 
When it was evident that renal proximal tubule cells as well as cochlear marginal and 
outer hair cells, share a unique mechanism to accumulate cisplatin and that DIPH 
can block this mechanism in vivo, the next step was to find an easier access to 
further characterize the transporter(s) involved in this process in more detail. For 
combining functional with molecular analyses, permanent cell lines established  from 
the primary target cells would be very valuable tools. As no established lines from 
stria vascularis marginal cells were available, a functional analysis was done with an 
epithelium cell line (TKPTS) deduced from proximal tubules of normal mouse kidney 
tissue.  
To investigate whether the protective effect of DIPH could be reproduced under in 
vitro conditions, TKPTS mouse kidney cells and, as a control, GM637 human skin 
fibroblasts were pre-incubated or not with DIPH (0.3 mM) and then treated with 
cisplatin in a dose-dependent manner. The accumulation of Pt-GG adducts in the 
nuclear DNA was analyzed at different time points by ICA analysis.  
No inhibitory effects of DIPH on the formation of cisplatin-DNA adducts were 
observed in both cell lines at four hours after drug exposure (Fig. 23). A similar result 
was obtained when the mouse kidney cells were incubated with cisplatin for 12 or 24 
hours (data not shown). Signs of apoptosis were visible in TKPTS cells when 
analyzed at 24 hours after cisplatin, independently whether they were pre-treated or 
not with DIPH (data not shown).   
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Fig. 23: Null effect of DIPH on the formation of Pt-GG adducts in the DNA of cisplatin-exposed 
murine proximal tubule cells and of human fibroblast cells in vitro. Cells of the lines TKPTS 
(established from renal proximal tubule of the mouse; A) and GM637 (human skin fibroblasts; B) were 
treated with different concentrations of cisplatin (black squares) or cisplatin plus DIPH (0.3 mM; 30 
minutes before cisplatin). After 4 hours cells were trypsinized, placed on slides, stained for Pt-GG 
adducts and measured by ICA analysis.  
 
 
   
 
Fig 24: DIPH does not reduce the cytotoxic effect of cisplatin in human lung cancer cells in 
vitro. Human lung carcinoma cells were left untreated (A), treated with 0.3mM DIPH (B), 5 μg/ml 
cisplatin (C) or cisplatin plus DIPH (D) for 24 hours. The percentages of apoptotic and necrotic cells 
were measured 24 h later by Annexin V-FITC and propidium iodide (PI) staining and FACS analysis. 
Early apoptotic cells are plotted in Q4 (Annexin V-FITC positive) and late apoptotic or necrotic cells in 
Q2 (Annexin V-FITC and propidium iodide positive) and and viable cells (unstained, Q3).  The fraction 
of apoptotic cells was significantly increased in cisplatin- (8 %; plot C) and cisplatin plus DIPH (11.2 %; 
plot D) treated cells as compared to the untreated control (2.3 %; plot A) and to cells exposed to DIPH 
alone (3 %; plot B) with no significant difference between the two cisplatin-treated cultures.  
 
 
The results suggest that the mechanism leading to the excessive DNA platination in 
proximal tubule cells in vivo is not active in the TKPTS cell line. This may be due to 
the fact that these cells have lost the expression of putative transporter for cisplatin 
A BTKPTS cells GM637 cells 
A C D B 
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uptake during the establishment of the permanent line from primary tubulus 
epithelium cells, or somehow have an altered their sensitivity to the inhibition by 
DIPH. 
In an additional set of experiments, several human cancer cell lines established from 
tumors, which are usually treated with cisplatin (lung, bladder, testis) were treated 
with cisplatin alone or in combination with DIPH.  Also here, inhibitory effects of DIPH 
were detected neither on the formation of DNA adducts (as measured by ICA) or on 
the induction of apoptosis (as measured by Annexin V staining and FACS analysis) 
(Fig.24 and data not shown). 
 
3.5 Co-administration of DIPH with repetitive cisplatin treatments diminishes 
the functional hearing loss in mice 
 
The next question asked was whether the DIPH-mediated protection of the cochlear 
target cells from excessive DNA platination also leads a reduction of the cisplatin-
induced hearing loss. In the clinical setting the ototoxic effect of cisplatin 
chemotherapy is observed only after several treatment cycles. To mimic this situation 
in our mouse model, animals were treated every second day with comparably 
moderate doses of cisplatin (5 mg/kg). A subgroup of the animals was additionally 
injected with DIPH (57 mg/kg) 30 minutes before each dose of cisplatin. Both groups 
received additional i.p. injections with saline solution (500 µl) in order to protect the 
mice from kidney injury. As controls, two further groups of animals received either 
only the inhibitor (DIPH group) or saline solution (negative control). At different 
cumulative doses of cisplatin all mice were measured for their functional hearing 
capability using the BAER test. For this test, the mice were relaxed by complete 
anaesthesia, positioned on a reclining table and clicks with a substantial frequency in 
the 1-3 kHz range were administrated at increasing levels of sound pressure between 
30 and 100 dB via adapted earphones. The neurosensoric waves along the central 
auditory pathway of the brainstem were measured by electrodes placed on the scalp 
and on each earlobe and were record as shown in Fig. 25. Like in the clinical BAER 
tests for humans, the hearing threshold was determined as the disappearance of 
wave V (Fig. 25 and Fig. 9). This value was converted into percentage of hearing 
capability as compared to the untreated controls (dB to %). The test was done for all 
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animals in this experiment also prior to treatment showing that they had a normal 
hearing capability. The mean value of the untreated mice was set as 100 %.  
 
Fig. 25: The measurement of hearing capacity in mice. (A) BAER test adapted to mice. Three 
needle electrodes were applied to pick up neuroelectrical signals from the hearing transmittal pathway. 
(B) Typical neurographic curve as recorded from sound stimulated, untreated control mice by the 
BAER test system for one sound pressure range. 
 
After reaching a cumulated cisplatin dose of 20 mg/kg, the BAER test was performed 
24 h after the last treatment. Mice that received only cisplatin showed a reduction of 
their hearing capability to about 50 % of the controls (Fig. 26). In contrast, the same 
dose of cisplatin, but in combination with DIPH, induced a hearing loss of only 20 % 
(Fig.26). Mice of the control and the DIPH alone groups did not show any difference 
in their hearing ability throughout the experiment. 
Another group of mice that received cisplatin in cumulated doses of 40 mg/kg plus 
DIPH still maintained a mean hearing capability of about 70 % of the untreated 
controls (Fig. 26). Importantly, all animals from the corresponding cisplatin-alone 
group displayed severe signs of acute toxicity before reaching that dose and had to 
be euthanized.  
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Fig. 26:  Protective effect of DIPH on the hearing capability of cisplatin-treated mice. To induce 
functional loss in the hearing system mice were treated repetitively 4 times with cisplatin alone 
(5mg/kg every second day, cumulated dose: 20 mg/kg) or with concomitant injections of DIPH (57 
mg/kg) 30 minutes before each dose of cisplatin. Additional groups were injected accordingly only with 
PBS or only with DIPH or were treated with cisplatin + DIPH eight times (cumulated dose of cisplatin: 
40 mg/kg). All animals were measured for their hearing capability with the BAER test 24 h after the last 
dose of cisplatin was applied. The columns represent mean values (+/- SD) from five animals per 
treatment group and were calculated as percentage of the control group. 
 
In all treatment groups of this experiment the mice were sacrificed immediately after 
the final BAER test and cochleae and kidneys were resected for the measurement of 
DNA platination by ICA analysis.  
A comparison of adduct levels in the different treatment groups was performed to find 
out whether repetitive low dose application of cisplatin induced the same pattern of 
DNA platination in both tissues as the acute high dose application, and whether the 
reduced hearing loss in the cisplatin plus inhibitor group was associated with a lower 
adduct accumulation in the critical target cells under these conditions. Massive 
adduct accumulation was found in the target cells of the two investigated organs, 
kidney and inner ear, from mice of the cisplatin alone group. In contrast, by far less 
adducts were found in the pertinent cells of the cisplatin plus DIPH treatment group. 
In the kidney all cells of the cortex depicted similarly low adduct levels with no 
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protruding proximal tubules visible (Fig. 27). Similarly, in the marginal and hair cells of 
the cochlea much lower adduct accumulation was observed in animals co-treated 
with DIPH as compared to the cisplatin alone group (Fig. 28). This protective effect 
was observed in all turns of the cochlea and was more pronounced in the marginal 
than in the outer hair cells. The adduct levels in other cell types of the inner ear 
remained unchanged by DIPH.  
Taken together, the results of this experiment strongly supported the notion that the 
excessive DNA damage in cochlear cells is the key trigger for the cisplatin-induced 
hearing loss and that an inhibitor-mediated reduction of that damage is a successful 
strategy to significantly prevent the functional loss. Noteworthy, the general health 
status of the mice in the cisplatin plus inhibitor group was better and weight loss was 
less severe than in the cisplatin alone group. A prolonged treatment of mice with 
DIPH alone up to eight applications had no obvious side effects.  
As it was assumed that the protective effect of DIPH for the cochlea was mediated by 
blocking an ion transporter being relevant for the physiological function of the target 
cells, an additional experiment was done to verify whether a treatment with DIPH 
alone alters the hearing capability of the mice. For this, five animals measured for 
their basal auditory sensitivity with the BAER test were treated 24 h later with a single 
dose of DIPH (57 mg/kg), and were re-examined one hour later again by the BAER 
test.  All mice depicted a slight reduction in their hearing capability from 100% down 
to 70%. When the BAER test was repeated 24 hours later all mice had regained their 
normal hearing sensitivity (graphs not shown). This observation further confirmed the 
idea that DIPH temporally blocks ion transporters in the inner ear and by that 
prevents cisplatin accumulation in the cochlear cells. 
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Fig. 27: Distribution of platinum adducts between different cells of the kidney cortex after 
repetitive cisplatin and cisplatin plus DIPH treatment. Mice were treated repetitively 4 times with 
cisplatin alone (5 mg/kg every second day, cumulated dose: 20 mg/kg) or with concomitant injections 
of DIPH (57 mg/kg) 30 minutes before each dose of cisplatin. Animals were sacrificed after the last 
BEAR test and Pt-GG levels in the DNA of kidney cells were visualized by immunostaining (red); DAPI 
- DNA (blue). Shown are representative micrographs of the adduct distribution in kidney cortex 
sections from both treatment groups. Left side: cisplatin plus DIPH; right side: cisplatin only. 
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Fig. 28: Distribution of platinum adducts between different cells of the cochlea after cisplatin 
and cisplatin plus DIPH treatment. Mice were treated repetitively 4 times with cisplatin alone (5 
mg/kg every second day, cumulated dose: 20 mg/kg) or with concomitant injections of DIPH (57 
mg/kg) 30 minutes before each dose of cisplatin. Animals were sacrificed after the last BEAR test and 
Pt-GG levels in the DNA of kidney cells were visualized by immunostaining (red); DAPI - DNA (blue). 
Shown are representative micrographs of the adduct distribution in kidney cortex sections from both 
treatment groups. Left side: cisplatin plus DIPH; right side: cisplatin only. 
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3.6 DIPH does not affect the therapeutic efficacy of cisplatin 
 
The pronounced protective effect of DIPH on both, DNA platination and functional 
loss in physiological target cells, made it an interesting candidate for co-application 
during cisplatin-based cancer therapy to reduce the side effects. An important factor 
that had to be controlled in this respect is whether DIPH not only reduces the severity 
of the side effects but also diminishes the efficacy of cisplatin-based cancer 
chemotherapy. Although experiments with various human cancer cell lines had 
indicated no inhibitory effect of DIPH on adduct formation and cytotoxicity induced by 
cisplatin (Fig. 24 and data not shown), the relevant mechanisms in primary tumor 
cells in situ might be completely different. Therefore, a suitable rodent tumor model 
was employed to further investigate this question. 
 
3.6.1 A mouse model for human lung cancer 
 
Oncogenic mutations in the gene encoding the small GTPase K-ras are among the 
most frequently detected alterations in human lung cancer and approximately 30 % of 
all cases of human non-small cell lung cancer (NSCLC) carry such an activated K-ras 
allele with mutations predominantly located in codons 12, 13 or 61. Based on this 
observation a mouse model for NSCLC was recently established (Sweet-Cordero et 
al., 2006; Oliver et al., 2010). The local activation of a silent transgenic K-rasG12D 
allele in these mice is achieved by intratracheal adenoviral transfection with the Cre 
recombinase (AdCre). The Cre recombinase cuts out a “stop” cassette and allows for 
expression of the oncogenic K-ras protein in transfected lung cells. When the 
initiation is performed at the age of 8 weeks, mice are diagnosed 16 weeks later with 
lung tumors at 100 % penetrance. The morphology and molecular characteristics of 
the tumors are very similar to human NSCLC and they respond with regression to 
chemotherapy with cisplatin (Oliver et al., 2010). Because cisplatin is a first line drug 
in treating human NSCLC, we employed this mouse model to investigate possible 
effects of DIPH on the treatment outcome of chemotherapy with cisplatin. The 
experiments were performed in the laboratory of Dr. Tyler Jacks at the MIT in 
Cambridge, Massachusetts. 
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3.6.2 No effect of DIPH on the DNA platination in primary lung tumor cells of 
cisplatin–treated mice  
 
Mice bearing K-rasG12D -induced lung tumors were divided into two groups for acute 
high dose and for chronic low dose treatment. Animals received mock-treatment with 
PBS or cisplatin alone or cisplatin plus pretreatment with DIPH. For acute treatment, 
the mice were i.p.-injected once with cisplatin (10 mg/kg) and for chronic treatment 
every second day with 5 mg/kg (4 consecutive injections, cumulative dose: 20 
mg/kg). DIPH was given at a dose of 57 mg/kg 30 minutes prior to each dose of 
cisplatin. All mice were sacrificed 24 hours after the last treatment and cochleae, 
kidneys and lungs were resected for analysis of DNA adduct accumulation. Whereas 
the protective effect of DIPH on the DNA platination in renal and cochlear target cells 
was present as expected from the previous experiments (data not shown), no 
reduction of the Pt-GG levels by DIPH co-treatment was measurable in lung tumor 
cells, independent from the treatment schedule (Fig. 29). Adduct levels were about 
two-fold higher after repetitive treatment as compared to single high dose treatment. 
These observations suggest that the pharmacodynamics of cisplatin in primary lung 
tumor cells of mice is different from the situation in the kidney and the cochlea, 
allowing for the severe side effects of the drug. Active uptake of the drug by a DIPH-
sensitive transporter does not seem to play a major role in the malignant lung cells, 
but could be confirmed for kidney and cochlear cells. 
 
3.6.3 Tumor growth controlled by cisplatin is not affected when combined with 
DIPH  
 
In addition to the analysis of adduct levels in the K-ras mouse model, we analyzed 
whether the co-administration of DIPH negatively affected the therapeutic efficacy of 
cisplatin in the NSCLC tumors. A cohort of tumor-bearing mice was randomly divided 
into three subgroups receiving different treatment regimens. Group one (mock 
treatment control) received i.p. injections once per week with PBS for 4 weeks. The 
second group received cisplatin treatment (7 mg/kg) once per week for 4 weeks, and 
mice of the third group were additionally pre-treated with DIPH (57 mg/kg) 30 minutes 
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before each dose of cisplatin. Mice were sacrificed 5 days after the last dose; lungs 
were resected and prepared for paraffin sections. Following H&E staining for 
morphological structures, the percentage tumor burden, the number of tumors per 
lung and the average tumor size was determined microscopically (Fig. 30, 31). In 
addition, kidneys were resected from all mice as internal control for correct cisplatin 
treatment and cryosections were analyzed by ICA for DNA platination (data not 
shown). By microscopic inspection of the stained lung section, it became obvious that 
the number of tumors per lung were higher in PBS-treated mice as compared to 
animals of the two cisplatin-treated groups (Fig. 30). For quantitative analysis we 
used the Bioquant image analysis software to blindly and randomly quantify the area 
of all lung tumors and the total lung surface area in 4 lung sections per mouse. The 
measurement revealed significantly lower average tumor sizes in both groups with 
cisplatin treatment as compared to the PBS control group and no difference between 
the cisplatin alone and the cisplatin plus inhibitor group (Fig. 31). The mean tumor 
burden in the lung, (as calculated from total area of tumor divided by total lung area), 
too, was significantly lower in both groups of cisplatin-treated mice with no significant 
difference if given alone or in combination with DIPH (Fig. 31). Tumor number was 
reduced in cisplatin and cisplatin plus DIPH treated mice, but these values were not 
statistically significant. This suggests that the drugs mainly reduce tumor growth and 
have less of an effect on tumor initiation. This hypothesis is further supported by the 
average tumor size data, and an observation that tumor growth is inhibited by 
cisplatin treatment as monitored by micro-CT (Oliver et al., 2010). In summary, the 
co-application of DIPH neither influenced the DNA damage level induced by cisplatin 
in primary lung tumors nor did it significantly hamper the therapeutic efficacy of the 
drug as determined by tumor burden and average lung tumor size.  
Based on all results obtained so far in our mouse models, it is concluded that during 
cancer chemotherapy with cisplatin the concomitant application of DIPH is a suitable 
and safe pharmacological strategy to prevent structural and functional damage in the 
inner ear and in the kidney without affecting the therapeutic response. 
 
  Results 
 
 
67 
   
cis cis+DIPH cis cis+DIPH
0.0
0.5
1.0
1.5
P
t-G
G
 in
 D
N
A
 (A
FU
)
 
 
Fig. 29: Accumulation of platinum-DNA adducts in primary mouse lung tumors during acute 
and chronic treatment by cisplatin or cisplatin plus inhibitor is not affected by the co-
application of DIPH. Animals were sacrificed 24 h after the last drug injection and lung cryosections 
were measured by ICA analysis  The two left columns represent mean adduct levels (+/- SD) in lung 
tumors cells of mice treated with cisplatin four times (5 mg/kg, every second day) with (cis+DIPH) or 
without (cis) co-application of DIPH (57 mg/kg). The two right columns refer to the respective adduct 
levels after a single high dose of cisplatin (10 mg/kg). 
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Fig. 30: Representative photographs of the H&E stained lung sections from tumor-bearing mice 
of from three treatment groups. Twelve weeks after tumor initiation mice were treated with cisplatin 
alone (7 mg/kg once a week for 4 weeks; C, D) or in combination with DIPH (57 mg/kg; G, H)) or were 
mock-treated with PBS (A, B, E, F). Five days after the last treatment lungs were resected, fixed in 
formalin and embedded in paraffin. Morphological structures were visualized in tissue sections (6 µm) 
by H&E staining (magnification: 2x). Tumor areas are stained dark purple. 
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Fig. 31: The co-application of DIPH had no inhibitory effect on the therapeutic efficacy of 
cisplatin on primary lung tumors in mice. Four tumor-bearing animals were treated with cisplatin 
alone or in combination with DIPH or were mock-treated with PBS. H&E-stained lung sections were 
analyzed quantitatively for the percentage of tumor burden (A), the average tumor size (B), and the 
number of tumors per section (C) by using Bioquant image analysis software. For none of these 
parameters a significant alteration was observed when comparing cisplatin and cisplatin plus DIPH 
treatment schedules.  
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3.7 Cisplatin resistance in the NSCLC mouse model 
 
Once the mouse model of human lung cancer was introduced, it was intensively 
studied for mechanisms of drug resistance as, similar to the clinical situation, a 
subset of tumors lost their responsiveness to cisplatin after several treatment cycles 
(Sweet-Cordero et al., 2006; Oliver et al., 2010). In the context of this study such 
tumors were investigated for the formation and persistence of platinum-DNA adducts 
in comparison to tumors still responding to the drug. 
 
3.7.1 Long-term cisplatin-treated lung tumors in mice exhibit reduced levels of 
DNA damage in response to a final dose of cisplatin 
 
30 mice bearing K-rasG12D -induced lung tumors were randomly divided into two 
groups and were long-term treated with cisplatin (7 mg/kg, i.p. once per week for four 
weeks) to select for drug resistance or were mock treated with PBS accordingly. After 
two weeks without treatment all mice got a final dose of cisplatin (7 mg/kg) and three 
animals were sacrificed at 4, 8, 16, 24 and 48 hours after the injection. Lungs were 
resected and cryosections were immuno-stained for Pt-GG adducts. In mice long-
term treated with PBS lung tumor cells regularly depicted Pt-GG adduct levels which 
were comparable to those in the surrounding normal lung cells, suggesting that 
formation and repair rates were similar in malignant and non-malignant cells (Fig. 32) 
The picture was different in the group of long-term cisplatin-treated mice where about 
20 % of the individual lung tumors analyzed by fluorescence microscopy showed 
strongly reduced or nearly undetectable levels of platinum-DNA adducts as early as 4 
h after a final dose of cisplatin (Fig. 32, lower panel). Interestingly, big differences 
were observed between single tumors from one animal (Fig. 33). However, tumors 
that had undetectable levels of platinum-DNA adducts at all time point were found 
only in lungs from long-term cisplatin-treated animals. 
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Fig. 32: Representative images of individual lung tumors stained for cisplatin-induced Pt-GG 
adducts in the nuclear DNA. Tumor-bearing mice were either long-term pre-treated with PBS (upper 
panel) or with cisplatin (lower panels) and were sacrificed 24 hours after a final dose of cisplatin. Left 
column: DAPI staining for DNA, medium column: immunostaining for DNA adducts, left column: 
overlay. Magnification: 10x.   
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Fig. 33: Individual tumors in the same lung area of a cisplatin-treated mouse exhibit different 
level of adduct accumulation. A mouse with lung tumors was long-term pretreated with cisplatin and 
was sacrificed 4 h after last administration. The immunostaining of lung sections for Pt-GG adducts 
revealed two adjacent tumors with different levels of DNA platination. The cells of the tumor on the left 
depicted none or very low adduct staining (red) whereas the nuclei of the tumor on the right (separated 
by the dotted line) show immuno-fluorescece signals similar to those of the surrounding normal lung 
tissue. Magnification: 20x. 
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3.7.2 Heterogeneity between individual lung tumors in mice  
 
To verify heterogeneity between all tumors, we scored all tumors blindly for absence, 
or presence of Pt-GG adducts. The numbers of tumors varied between the cisplatin 
and the PBS treatment groups, so we grouped the tumors into three categories:  
tumors with very low or absent adducts, tumors with low adducts and tumors with the 
same adduct level as the surrounding tissue (Fig. 32). This analysis was done at four 
time points: 4, 8, 16 and 24 hours. At the latter time point, the tumor cells may 
already have replicated their DNA and underwent cell division, which would reduce 
the adduct levels independently from repair processes. 
It was noted that the percentage of tumors with low or absent adducts in the long-
term cisplatin-treated group increased with time (Fig. 34). These data allow to 
conclude that Pt-GG adducts are present in sensitive and most resistant tumors at 
early time points, but are cleared more rapidly in non-responsive tumors pretreated 
with cisplatin. 
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Fig. 34: Number of lung tumors with different levels of DNA platination in two treatment group. 
Tumor-bearing mice were either long-term (4 weeks) pretreated with cisplatin (cis) or were mock-
treated (PBS), All animals received a final dose of cisplatin (7 mg/kg) in week 6 and 3 mice were 
sacrificed at 4, 8, 16 or 24 h after the last dose of cisplatin (0h PBS and 0h cis: without last dose). 
Deep red – sensitive to cisplatin tumors (high adduct level), red – low adduct level tumors, light pink – 
tumors with very few adducts. In cisplatin treated group number of tumors analyzed: 4 hours - were 
analyzed 26 tumors; 8 hours - were analyzed 22 tumors; 16 hours - were analyzed 32 tumors; 24 
hours - were analyzed 38 tumors. In long-term PBS treated group: 4 hours - were analyzed 41 tumors; 
8 hours – were analyzed 20 tumors; 16 hours - were analyzed 29 tumors; 24 hours – were analyzed 
26 tumors. The table below indicates exact percentage number with different adducts. 
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  4. Discussion 
 
The antineoplastic chemotherapy with cisplatin, although, effective in many cases, is 
hampered by serious limiting factors such as severe side effects and primary or 
acquired resistance often occurring during repetitive courses of treatment. Such side 
effects make the reduction of dosage, frequency or duration of cisplatin therapy 
necessary. One of the major side effects of cisplatin, its nephrotoxicity, can be 
reduced by forced diuresis before and after drug administration.  The ototoxicity of 
cisplatin is still a serious clinical problem. Future efforts should be aimed at the 
development of methods to efficiently protect the inner ear tissue during 
chemotherapy. In the recent years, numerous suggestions have been made for 
pharmacological strategies to prevent cisplatin-induced hearing loss (van den Berg et 
al., 2006). From the clinical perspective, it is absolutely necessary that such a 
preventive strategy does not interfere with the antineoplastic efficacy of the drug. To 
develop rational strategies for preventive interventions, it is crucial to investigate the 
molecular mechanisms underlying the hypersensitivity of cochlear cells to cisplatin. 
The primary aim of this thesis was to study the molecular events resulting in cell 
damage in the inner ear and in hearing dysfunction after cisplatin administration, as 
well as to identify putative inhibitors of cisplatin cytotoxicity in normal tissues. 
  
 4.1 Cell type-specific accumulation of Pt-DNA adducts coincides with the 
cytotoxicity of cisplatin in normal tissues  
 
The main mechanism by which cisplatin exerts its cytotoxicity in tumor cells is 
believed to involve the formation of intra- and interstrand adducts in the nuclear DNA. 
Persisting platinum adducts may lead to the inhibition of replication and transcription 
processes as well as to cell cycle arrest, and can result in apoptotic cell death 
(Jordan et al., 1998; Ang et al., 2010).  
Regarding cisplatin ototoxicity, numerous mechanisms that may lead to functional 
disturbance or death of non- or slow-dividing cells of normal tissues were suggested 
during the recent years. Most frequently discussed are (i) the generation of reactive 
oxygen species (ROS), (ii) damage of mitochondrial membranes and (iii) drug-
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induced mitochondrial apoptosis (Devarajan et al., 2002; Peters et al., 2003; Santos 
et al., 2007; Kim et al., 2010). However, previous in vivo studies in our own group in 
cisplatin-treated guinea pigs observed that the level of 8-oxoguanine (a lead type of 
ROS-induced DNA damage) was not increased in the DNA of inner ear cells after 
cisplatin administration (Thomas et al., 2006). Most other investigations detected 
ROS production only in cisplatin-exposed cochlear explants and in short-term 
cultures ex vivo (Dehne et al., 2001).  
The formation rate of cisplatin-induced DNA damage is cell-type specific, and occurs 
in the inner ear predominantly in two types of cells, the marginal cells of the stria 
vascularis and the outer hair cells of the organ of Corti. Early observations on cell 
type specificity of cisplatin-induced damage in the inner ear were made using 
electron microscopy (Nakai et al., 1982; Kohn et al., 1988), and were supported by 
DNA damage analysis in guinea pigs later on (Thomas et al., 2006). In the present 
study, it was aimed to further clarify the molecular mechanisms of cisplatin 
ototoxicity. Thus, a mouse model was established, which allowed the analysis of 
electrophysiological parameters of hearing capability and, simultaneously, of the 
formation and processing of Pt-DNA adducts at the level of individual cells. The 
degree of cisplatin-induced DNA damage and its repair was measured in different 
types of inner ear and kidney cells. This study shows for the first time that the DNA in 
outer hair cells and marginal cells of the cochlea is extensively damaged in cisplatin-
treated mice. Up to eight-fold differences between the various cells layers in the stria 
vascularis as well as between the outer hair cells and other cell types of the organ of 
Corti were observed. A similar erratic distribution of the DNA platination was detected 
throughout kidney cortex cells, with high levels in proximal tubular cells as compared 
to other kidney cortex cells. These observations strictly contradict the assumption of 
passive diffusion as the exclusive or main route of cisplatin to enter such cells. More 
likely, the active import of cisplatin by membrane transporters may play a role for the 
distinct distribution of DNA platination products within a given tissue. The finding of 
similarly high platinated cells within two structurally and functionally unrelated tissues 
might indicate a causative role of channels or transporters expressed in the kidney as 
well as in the cochlea. Such a common mechanism was recently discussed by Lang 
et al. who suggested that simultaneous dysfunction of seemingly unrelated organs 
might be based on a common defect of channels or transporters (Lang et al., 2007). 
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A number of clinical observations documented that almost all ototoxic agents also 
have nephrotoxic effects (Rybak and Ramkumar, 2007; Lang et al., 2007). Due to its 
comparatively small size (MW: 300), it is likely that cisplatin is aberrantly recognized 
as a substrate by specific membrane transporters in the target cells of the inner ear 
and the kidney (Lang et al., 2007).  
 
4.2 Quantification of Pt-DNA adducts in different turns of the cochlea 
 
Cisplatin-induced dysfunction of the hearing system has been shown to begin in the 
basal turn of the cochlea, leading to a functional loss for high frequencies (Böheim 
and Bichler, 1985; Sluyter, 2003; Laurell et al., 2007). In this study, remarkable 
differences were found in DNA adduct accumulation between the basal and the 
apical turn, not only for the marginal cells, but also for other cells of stria vascularis. 
The mechanism underlying the differential distribution of cisplatin between the 
cochlea turns is not known, but might be determined by the morphological structure 
of the cochlea and the blood stream through the stria vascularis. Indirect 
measurements have shown that radioactively labeled cisplatin is first accumulated in 
the stria vascularis and then distributed among other cells of the inner ear 
(Schweitzer et al., 1986). The higher content of DNA adducts in the basal turn 
marginal cells found in this study corresponds to the higher degree of destruction of 
the tissue in the basal turn of the cochlea, and is in line with the early onset of 
hearing loss for high frequencies recorded in rodents and humans (Sluyter, 2003; 
Rybak and Ramkumar, 2007).  
 
4.3 The activity of nucleotide excision repair in processing of Pt-DNA lesions in 
inner ear cells  
 
The adduct formation in DNA by cisplatin is influenced by different pharmacokinetic 
and pharmacodynamic factors of the drug, such as chemical absorption, distribution, 
metabolism or renal excretion (O'Dwyer et al., 2000). Once adducts are formed, their 
removal depends on the activity of DNA repair processes. In the case of cisplatin, the 
elimination of adducts is mediated predominately by the nucleotide excision repair 
(NER) system. The functional capacity of NER is assumed to be rather 
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inhomogeneous among different cell types (Kelland, 1994) and the deficiency for 
distinct repair proteins leads to an increased vulnerability of the cell. For example, 
deficient repair of Pt-DNA adducts was identified in human testicular cancer cells, 
which are highly sensitive to cisplatin (Bedfort et al., 1988; Hill et al., 1994; Köberle et 
al., 1997; Köberle et al., 2010). The in vivo measurement of repair kinetics in this 
study showed high NER activities in the target cells of the inner ear and were 
comparable to those in the non-target cells of Reissner’s membrane. The data 
exclude insufficient DNA repair as the cause of the excessive DNA platination in 
outer hair cells and marginal cells. Furthermore, these findings in mice were in line 
with previous observations in guinea pigs (Thomas et al., 2006). Interestingly, long 
term kinetics in other tissues (e.g. liver, kidney and neurons) of cisplatin-treated, 
NER-proficient mice, revealed that a certain proportion of adducts persisted 
unrepaired even five days after drug administration (Liedert et al., 2006; Dragnidze et 
al., 2007). 
 
4.4 The role of the NER protein XPA in the cells of the hearing system 
 
Functional DNA repair is critical for the viability of cells, particularly during acute 
genotoxic stress. The XPA protein plays a central role in the NER pathway by 
recruiting several other NER proteins, which build the repair incision complex at the 
damaged site. 
In the present work, XPA-knockout mice defective in both sub-pathways of the NER, 
were used to study the influence of this repair system on the cytotoxicity of cisplatin 
and the processing of Pt-GG adducts. The experiments revealed that XPA-deficient 
mice were highly sensitive to the general toxicity of cisplatin, accompanied by a high 
accumulation of adducts in cochlear cells and a decrease in hearing performance. 
The data presented here strongly supports the hypothesis that the cisplatin-induced 
DNA adducts initially trigger cellular processes finally leading to functional 
sensorineural hearing loss. In contrast, several other reports have accused the 
generation of ROS to be causative for the ototoxicity of the drug by promoting 
apoptotic and necrotic cell death in cochlear tissue (Albinger-Hegyi et al., 2006; 
Santos et al., 2007; Rybak et al., 2007; Rybak and Ramkumar, 2007). However, 
none of the preventive approaches for ototoxicity (as well as nephrotoxicity) based on 
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the reduction of ROS during cisplatin treatment were ever validated in clinical trials 
(van den Berg et al., 2006; Yao at al., 2007). In addition, no convincing biochemical 
mechanism has been suggested until now to explain the direct or indirect modulation 
of ROS levels by cisplatin. 
 
4.5 A putative transport system for cisplatin in normal tissues 
 
Several previous studies on the cellular uptake of cisplatin assumed an inert 
transport through the membrane as the predominant route of entrance of the drug 
(Gale et al., 1973; Ogawa et al., 1975; Andrews at al., 1988; Mann et al., 1990). 
Experiments with cancer cell lines revealed passive transport to be responsible for 
50% of the influx (% of drug molecules per cell). The other half of influx of cisplatin 
molecules was attributed to unknown transporters (Dornish et al., 1986; Gately and 
Howell, 1993). More recent studies further support the concept of active transport 
mechanisms in distinct cell types (Andrews and Albright, 1991; Komatsu et al., 2000; 
Katano et al., 2003; Sinani et al., 2007; Blair et al., 2010).  
Two main families of importers that recognize cisplatin as a substrate have been 
described so far (Pabla and Dong, 2008). One of them is the high-affinity copper 
transporter CTR1. However, organs with a high copper metabolism, such as liver and 
brain, accumulate comparatively low levels of Pt-DNA adducts (Liedert et al, 2006; 
Dzagnidze et al., 2007) and do not show signs of cisplatin toxicity. In contradiction, 
an increase of cellular uptake of either copper or cisplatin by CTR1 was shown to 
reduce the uptake of the other, and the exposure to both substances trigger the 
delocalization of CTR1 from the membrane. Cells lacking functional CTR1 lost their 
sensitivity to cisplatin (Ishida et al., 2002) and overexpression of CTR has been 
shown to increase the cellular sensitivity to cisplatin (Song et al., 2004). Inversely, the 
overexpression of the copper efflux transporter ATP7B (ATPase, Cu++  transporting, beta 
polypeptide), was associated with resistance of cancer cells to cisplatin (Nakayama et 
al., 2002, Kuo et al., 2007). The role of these transporters in ototoxicity or 
nephrotoxicity has not yet been investigated in animal models despite of some 
evidence for CTR1 being highly expressed in mouse kidney cells (Kuo et al., 2006). 
In addition to increasing the cellular sensitivity for cisplatin, CTR1 overexpression has 
also been shown to increase the cellular sensitivity to carboplatin (Song et al., 2004). 
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This finding may mean that CTR1 is unlikely to represent the major mechanism for 
the ototoxic effect of cisplatin, since carboplatin is not particularly ototoxic in patients, 
and does not depict high adduct accumulation in marginal cochlear cells or renal 
proximal tubular cells of drug-exposed guinea pigs (Thomas et al., 2006).  
The second transporter family which may be involved in the import of platinum 
complexes are the organic cation transporters (OCTs). OCTs mediate the transport 
of cationic compounds through the basolateral membrane of epithelial cells (Fig. 35). 
Three members of this family, OCT1, OCT2 and OCT3, are currently under 
discussion to account for the side effects of cisplatin (Motohashi et al., 2002; 
Yonezawa et al., 2005). In a study with MDCK canine kidney tubular cells it was 
demonstrated that the drug-induced nephrotoxicity was related to basolateral 
transport of cisplatin into proximal tubular cells (Ludwig et al., 2004). The toxic effect 
was higher when the drug was administrated to the basolateral side of the cells as 
compared to the apical side. OCT2 has been reported to be highly expressed in the 
kidney, while other members of the OCT family are expressed predominantly in other 
tissues: OCT1 in the liver and OCT3 in the heart, intestine and brain (Alnouti et al., 
2006; Nies et al., 2009). Only very few published data are available about the 
expression and distribution of OCT transporters in the cochlea.  
The functional inhibition of membrane transporters by small molecules is a possible 
strategy to pharmacologically modulate the uptake of substrate molecules. For the 
family of OCT transporters, several potential inhibitors have been tested so far. 
Cimetidine has been reported to specifically interfere with OCT2, and to reduce the 
influx of cisplatin into proximal tubular cells (Ludwig et al., 2004). Conversely, the 
overexpression of OCT2 highly sensitized human embryonic kidney cells to the 
cytotoxic effects of cisplatin (Müller et al., 2005; Yonezawa et al., 2005; Ciarimboli et 
al., 2005). A further proof for OCT2 to represent a main factor for the nephrotoxicity 
of cisplatin came from the observation that proximal tubule cells established from a 
human diabetic kidney exhibited reduced uptake of in the drug. This observation 
might be connected to the lower expression of OCTs in diabetes (Thomas et al., 
2004; Yao et al., 2007). Finally, the two other platinum complexes, carboplatin and 
oxaliplatin, which were shown to have no noteworthy ototoxic or nephrotoxic 
potentials, were demonstrated not to interact with OCT2 (Ciarimboli et al., 2005). 
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Due to the above mentioned reasons, the local expression in the inner ear of six 
different proteins of the OCT family was determined in this study by immunostaining 
of mouse cochlea tissue using a panel of specific antibodies. Only the transporters 
OCT2 and OCT3 were found to be present at high levels, whereas the other four 
(OCT1, OCTN1, OCTN2, OCTN2) were not detected. This finding correlates with a 
recently published study showing OCT2 expression in the organ of Corti and the stria 
vascularis of mice (Ciarimboli et al., 2010). It is interesting to note that the expression 
of OCT2 and OCT3 transporters in intermediate and basal cells of the stria vascularis 
and in the supporting cells of the organ of Corti does not fit to the distribution of DNA 
adducts in the cochlear which is comparatively low in just those cells. In conclusion, 
the identity of the hypothetical membrane transporter importing cisplatin into the 
critical target cells remains obscure yet. Another model for the particular cytotoxicity 
of cisplatin in the marginal cells was published by Laurell et al. (2006), The authors 
suggested that the drug is actively imported into the intermediate cells of the stria 
vascularis, which contain high levels of melanin. This pigment is known to form 
complexes and, thereby, detoxifies cisplatin. As soon as this protective mechanism is 
exhausted and the cells have lost their structural integrity the neighboring marginal 
cells are targeted by the cytotoxic effect of the cisplatin (Schweitzer, 1993; Takeuchi 
et al., 2000). However, this model is not supported by our data since the high 
accumulation of DNA adducts in the marginal cells is observed already a few hours 
after application of the drug and long time before structural alterations can be 
detected . 
 
4.6 Screening for a pharmacological inhibitor of cisplatin-induced ototoxicity 
 
Although there had been numerous attempts to identify molecules which modulate 
the transport of cisplatin into physiological cells or diminish its toxicity,  in most cases 
the protective activity of such compounds was  proven only in cell culture systems 
and not under in vivo conditions (Pfaller and Gstraunthaler, 1998; Chan et al., 2007; 
Rybak et al., 2007). In this study, several of those compounds were examined in an 
established mouse model for cisplatin-induced ototoxicity. Here, it was clearly 
demonstrated that famotidine, probenecid, fluoxetine, desloratadine, quinine and 
butylscopolamine do not reduce the accumulation of cisplatin-DNA damage in the 
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target cells of renal and inner ear tissues. There had been reports on in vivo 
experiments for ranitidine and cimetidine without conclusive results (Dorr and Soble, 
1988; Ott et al., 1991; Fisher and le Couteur, 2001; Erhsson and Wallin, 2010). In the 
present study, it was demonstrated for the first time that the co-application of 
diphenhydramine (DIPH) significantly reduces both, the excessive DNA platination in 
the critical inner ear cells and the functional loss in the hearing system.  
DIPH was discovered initially as an antihistaminic agent, which ameliorates motion 
sickness (Garnett, 1986; Harris, 2008). Since then, a number of structurally or 
functionally related substances have been evaluated, some of which were also 
included in this study (fluoxetine, ranitidine, cimetidine, desloratadine). They differ 
only slightly in their antihistaminic activity, mostly with respect to duration. The 
precise mechanism, however, is not completely understood. They have little effect on 
either apomorphine- or copper sulfate-induced emesis and there is little correlation 
between their antihistaminic or anticholinergic potency and their antiemetic effects. 
All compounds were shown to have a narrower spectrum of antiemetic activity than 
compounds of the phenothiazine group, being used predominantly for the treatment 
of motion sickness and vestibular disturbances (Harris, 1978). Among the drugs 
tested in this study, DIPH was the only antihistaminic agent that displayed a 
significant activity in preventing the formation of platinum adducts in critical target 
cells. Therefore, the pharmacological effects such as histamine antagonism, 
serotonin re-uptake inhibition, anti-cholinergic activity or muscarinic receptor 
antagonism, which DIPH has in common with other antihistamines, could most likely 
be excluded from being responsible for the reduced accumulation of DNA adducts in 
cochlear and kidney cells. Thus, the nephro- and oto-protective activity of DIPH is 
more likely to be due to the interference with a so far unidentified transporter 
expressed in the target cells.  
Theoretically, there are different mechanisms that could be triggered by DIPH leading 
to reduced levels of DNA platination in the target cells: (i) a decrease of the uptake or 
an increase of the export of cisplatin in such cells, (ii) its accelerated metabolic 
deactivation, or (iii) an augmented repair of the DNA adducts. The findings in this 
study clearly exclude an effect of DIPH on the DNA repair capacity of cochlear and 
kidney cells.   
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The cells in focus are all characterized by their distinct profiles of multiple membrane 
transporters ensuring their functionality in the respective tissues (Kendall et al., 1983; 
Inui, Masuda and Saito, 2000; Lang et al., 2007). The strictly dose-dependent 
pharmacological inhibition of DNA platination by DIPH in the target cells, but no 
influence on other surrounding cells supports the hypothesis of DIPH binding to, and 
thereby blocking, specific transporters on the target cells. In an attempt to further 
characterize this transport mechanism, the influence of DIPH on the accumulation of 
Pt-GG adducts was analyzed in a cell line established from kidney proximal tubule 
cells of the mouse. The null-effect of DIPH in that cell system points to a functional 
loss of the putative drug importer, and again underlines the basic necessity of 
analyzing such mechanisms under in vivo conditions. One reason for seeing no 
protective activity of DIPH may be the due to the fact that epithelial cells of the 
proximal tubules are highly orientated in the kidney. There are a number of 
transporters in the basolateral membrane of the kidney, and different patterns of 
transporters in the brush border membrane orientated to the inner lumen of the 
tubule (Fig. 35). These transporters are regulated by the concentrations of different 
ions and molecules around both membranes. When cultivating such cells ex vivo, 
they do not have natural barriers as they would in the intact kidney tissue, and might 
have lost the expression of cell-type specific membrane components during the 
process of immortalization.  
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Fig. 35: Uptake and efflux transporters in proximal tubule epithelium cells of the kidney. The 
figure depict the localization of some transporters in  the basolateral (left) and the brushborder (right) 
membranes. OCT: organic cation transporter; OAT: organic anion transporter; OATP: organic anion 
transporting polypeptides; URAT1: urate transporter 1: PEPT1-2: solute carrier for oligopeptides; MRP: 
multidrug resistance-related protein transporter; MATE: multidrug and toxin extraction protein; PgP; P-
glycoprotein; OCTN1: organic cation/ergothioneine transporter; OCTN2: organic cation/carnitine 
transporter. (Figure adopted from Giacomoni et al., 2010) 
 
4.7 DIPH prevents cisplatin-induced ototoxicity in mice 
 
Cisplatin chemotherapy is usually applied in the clinic in repetitive treatment cycles, 
and thus, leads to progressive and permanent hearing loss. In cases of successful 
therapy, most of the patients, and in particular treated children, suffer from the toxic 
side effects for the rest of their lives. In this study, clinically relevant degrees of 
hearing loss were measurable in mice treated repetitively with low doses of cisplatin 
and a strong reduction of this side effect was observed when DIPH was given prior to 
each treatment cycle. Furthermore, it was demonstrated for the first time that 
unrepaired platinum-DNA adducts in the target cells represent the critical triggers for 
cisplatin toxicity and that the severity of the side effects is strictly correlated to the 
amount of drug-induced DNA damage. The precise mechanism by which persisting 
Pt-(GG) intrastrand cross links lead to structural alterations and functional impairment 
in terminally differentiated G0 cells is still unknown. One current hypothesis highlights 
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the role of autophagy in this process. Autophagy is a genetically programmed 
mechanism for cell survival during different stress conditions, such as energy 
starvation or exposure to cytotoxic agents (Rosenfeld and Ryan, 2009). The 
underlying processes are complicated and usually mediate the balance between pro-
apoptotic and pro-survival signals (Tang et al., 2010). Autophagy has been observed 
in a variety of tumors as a response to DNA damaging agents (Degenhardt et al., 
2006; Jin and White, 2007). This study suggests that a similar process might also be 
triggered in the highly damaged cochlear cells of mice after repetitive treatments with 
cisplatin. Micromorphological analyses by electron microscopy revealed numerous 
large autophagosomes containing a bulk of cytoplasmic organelles in these cells (Fig. 
36 and 37). Such alterations are generally indicative for autophagic or necrotic 
processes rather than for survival or apoptosis (Yu et al., 2006; Gozuacik and Kimchi, 
2007; Galuzzi et al., 2008). No signs of autophagy or necrosis were recorded in the 
respective cells from animals treated with DIPH alone or from untreated controls, and 
autophagosomes were much less frequent and properly shaped in cochlear cells of 
mice treated with cisplatin plus DIPH.  
A possible model to explain how cisplatin-induced DNA adducts may trigger 
physiological, non-dividing cells to undergo such dramatic alterations and finally lose 
their functionality might be based on the following observations: The activation of 
autophagic rescue programs after cytotoxic stress strictly depends on the availability 
of the “high mobility group” protein HMGB1 in the cytoplasm of cells (Tang et al., 
2010). Earlier studies have shown a very strong binding of HMGB1 to cisplatin-
modified DNA structures (Chow et al., 1995; He et al., 2000), so that high levels of 
Pt-GG adducts may trap all of the protein in the nucleus, and thereby, prevent its role 
in balancing the autophagic process in favor of cell survival. According to this model 
a reduced adduct accumulation in the target cells by co-application of DIPH would 
result in diminished functional impairment of those cells. Whether this hypothesis 
reflects the mechanism of cisplatin ototoxicity in mice as well as in patients remains 
to be proven. 
 
      Discussion 
 
 
86 
 
 
 
 
Fig. 36: Micromorphology of outer hair cells in the cochlea of mice: Comparison of different 
treatment conditions. Mice were repetitively treated every second day for four times with PBS 
(“Control”), or with DIPH (57 mg/kg; “Inhibitor”), or with cisplatin (5 mg/kg; “Cisplatin”) or with both 
drugs (“Cisplatin plus Inhibitor”) and outer hair cells in the middle turns of the cochleae were visualized 
in ultrathin sections by electron microscopy. The morphology of the cytoplasm was normal without any 
sings of autophagy in PBS- as well as in only DIPH-treated mice. Cochleae from mice treated with 
cisplatin plus DIPH depicted rare autophagosome-like structures (arrow). in the cytoplasm. Treatment 
with cisplatin alone caused necrotic cell death as indicated by incomplete and lumpy autophagosomes 
(arrow) as well as cellular swelling, and scattered chromatin condensation.  
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Fig. 37: Micromorphology of stria vascularis marginal cells in the cochlea of mice: Comparison 
of different treatment conditions. Drug exposure and analyses were done as given in Fig. 36. No 
signs of autophagic processeses were observed in control as well as in DIPH allone-treated animals 
(“Inhibitor”), whereas rare, well-shaped autophagosomes were detectable after a combined application 
of DIPH and cisplatin (“Cisplatin plus Inhibitor”). At a higher magnification (bottom image) embedded 
mitochondrial bodies became visible in such double membrane-coated phagosomes. After cisplatin 
alone-treatment (lower right) most of the marginal cells contained multiple, densely packed autophagic 
vesicles (see arrows).  
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4.8 DIPH diminishes side effects of cisplatin without affecting the anti-cancer 
efficacy 
 
Since the severe side effects of cisplatin were already recognized in early clinical 
trials, numerous pharmacological, molecular, and genetic approaches have been 
suggested to circumvent the neuro-, nephro- and ototoxicity of the drug (Hanigan et 
al., 1994; Hanigan et al., 2001; Tsuruya et al., 2003; Yu et al., 2005; Jiang et al., 
2007; Santos et al., 2008). None of these preventive strategies reached the clinical 
level, although the majority of them had demonstrated their effectiveness in animal 
models. The major obstacles derived from warrantable concerns regarding putative 
negative effects of such strategies on the tumor-therapeutic efficacy of cisplatin, 
Therefore, there was an urgent need to address this problem carefully when 
developing novel approaches. 
Lung cancer is the leading cause of cancer death world wide, and non-small cell lung 
cancer (NSCLC) accounts for approximately 80 % of the cases (Greenlee et al., 
2001). This malignancy is frequently associated with mutations in the gene coding for 
the small GTPase K-ras and is usually treated with cisplatin-based combination 
therapies. The use of genetically engineered mice carrying a silent oncogenic K-ras 
transgene, which can be activated in a controlled manner, provides a model that 
closely recapitulates many aspects of human lung oncogenesis (Johnson et al., 
1997; Jackson et al., 2001; Guerra et al., 2003; Sweet-Cordero et al., 2004). The 
molecular similarity between K-ras-initiated murine lung tumors and the human 
NSCLC suggests that this is a relevant model to investigate the molecular 
mechanisms of chemotherapy response. In order to explore whether DIPH might 
have an effect on the anticancer activity of cisplatin in this model, renal, cochlear and 
lung tumor tissues were examined for DNA adduct accumulation after short-term and 
long-term treatments. Furthermore, the average tumor volume and the percentage of 
tumor burden were measured in animals treated with cisplatin alone or in 
combination with the inhibitor The results clearly support the hypothesis that DIPH, 
while efficiently protecting the target cells in the kidney and the inner ear, did not 
have any significant effect on the levels of DNA adduct accumulation in the tumor 
cells. Moreover, DIPH did not influence the tumor response during several cycles of 
chemotherapy with cisplatin. In conclusion, this study uncovered the highly protective 
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role of DIPH for the target cells of cisplatin toxicity, while retaining the pro-apoptotic 
role of cisplatin in primary lung tumor cells in vivo. 
 
4.9 Enhanced DNA repair in a mouse model of cisplatin-resistant lung cancer 
 
Despite the widespread clinical use of conventional chemotherapeutic agents such 
as cisplatin, the precise mechanisms underlying the non-responsiveness of tumors to 
these drugs are still poorly understood. This lack of knowledge is, at least partly, due 
to the fact, that most of the previous studies on cisplatin sensitivity / resistance have 
utilized tumor cell lines in vitro to generate resistant sub-clones. While this 
experimental approach has revealed a broad spectrum, of particular mechanisms 
which can alter the cellular drug sensitivity in vitro, they may differ significantly from 
those used in primary tumor cells in vivo (Fink et al., 1997; Siddik, 2003; Wang and 
Lippard, 2005). A major reason for the diverse behavior could be, that In vivo 
resistance develops in response to repeated low doses of cisplatin whereas  in vitro 
resistance is a rapid adaptation to high doses of the drug given over a short period of 
time. 
 
Genetically engineered animal models for particular malignant diseases are powerful 
tools, which have not yet been fully exploited to address the problem of drug 
resistance. Here, the effects of cisplatin treatment in an oncogenic K-ras-driven 
mouse model of human lung cancer were characterized. 
The loss of sensitivity to cisplatin-based chemotherapies in human cancer is 
assumed to be a complex, multifactorial process, as no single factor has been able to 
explain resistance in full. The mechanisms most frequently discussed during the last 
years were decreased uptake, intracellular detoxification, increased efflux, tolerance 
to high adduct levels by translesion DNA synthesis via specialized polymerases or 
accelerated repair of drug-induced DNA damage. In the murine lung cancer model 
employed in this study, significantly decreased levels of platinum adducts were 
observed 24 hours after a final dose of cisplatin in resistant tumors of long-term 
treated mice as compared to still responding tumors in the control group (Fig. 32 and 
34, Oliver et al., 2010). Adduct levels in normal lung cells adjacent to the resistant 
tumors were generally unaltered (Oliver et al., 2010). Furthermore, atomic absorption 
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spectroscopy studies did not reveal a significantly decreased overall concentration of 
platinum within the tumor areas, demonstrating that cisplatin was able to enter 
tumors similarly in long-term cisplatin and in PBS-treated tumors (Oliver et al., 2010). 
The repair kinetics in the analyzed tumors support the idea of increased repair 
capacity, rather than reduced adduct formation rates, as the reason for the low levels 
of DNA damage in malignant cells no longer responding to the therapy. These 
findings are in line with clinical observations of NSCLC tumors having a 
comparatively poor prognosis for treatment outcome. These tumors often depict high 
expression levels of the DNA repair protein ERCC1, a rate-limiting component of the 
NER pathway (Olaussen et al., 2006). 
The data presented here demonstrated for the first time that enhanced DNA repair 
causes chemotherapy resistance in an in vivo NSCLC mouse model. In combination 
with the data from a recently published paper (Oliver et al., 2010), this supports the 
idea that the predominant mechanism leading to the therapeutic failure of cisplatin 
treatments in vivo may be based on accelerated DNA repair (Read, 1998; Martin et 
al., 2008).  
 
4.10 Conclusions and outlook 
 
The results obtained in this study strongly highlight the analytical power of the 
antibody-based measurement of cisplatin-induced DNA adducts at the level of 
individual cells. In combination with informative mouse models this technique enabled 
new insights into the cellular mechanisms which underlie the two major clinical 
problems associated with cisplatin-based chemotherapies, the occurrence of tissue-
specific toxicity and the development of drug resistance in tumors. The precise 
knowledge of these mechanisms is an indispensable prerequisite for the 
development of successful interventions aiming to reduce or eliminate the side 
effects ant to improve the therapeutic benefit. Thus, the identification of DIPH as a 
potent inhibitor of the cisplatin-mediated oto- and nephrotoxicity was enabled after 
aberrant import of the drug into the target cells was pinpointed as the critical 
mechanism. After having shown that primary lung tumor cells in mice and also 
human lung cancer cell lines lack such transporter activities the clinical application of 
DIPH during cisplatin treatment can be promoted. The design of future clinical studies 
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with DIPH is facilitated to a great deal because it is an approved drug and has 
already been used in cancer chemotherapies as an anti-vomiting agent. 
With respect to the problem of drug resistance this study demonstrated for the first 
time that the non-responsiveness observed in individual lung tumors after several 
cycles of cisplatin treatment is correlated to strongly reduced levels of drug-induced 
DNA damage. The data obtained so far in this study argue for the enrichment of 
highly repair competent cells in such tumors under the selective pressure of repetitive 
cisplatin chemotherapy. Future clinical studies with NSC lung cancer patients have to 
show whether this mechanism is also relevant for human malignancies. 
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5. Summary 
 
Cisplatin is one of the most commonly used tumor-chemotherapeutic agents. It is 
highly effective in testicular cancer and is a central component of treatment regimens 
for several other malignancies including esophageal and lung cancer. While much is 
known about the molecular mechanism by which cisplatin induces apoptosis in 
proliferating tumor cells, it is still poorly understood, why this drug also leads to fatal 
dysfunction and cell loss in particular normal tissues such as the inner ear, the 
kidney, and the peripheral nervous system. These side effects strictly limit desirable 
dose escalations and severely reduce the quality of life of treated patients. This work 
aimed to answer some of the open questions and, based on the results, tried to 
develop a novel strategy for reducing the systemic toxicity of cisplatin in normal 
tissues.  
Employing a mouse model for cisplatin-induced ototoxicity and a sensitive, antibody-
based technique to measure cisplatin-DNA adducts in the nuclei of individual cells it 
was possible to identify two particular cell types in the inner ear which accumulated 
excessive amounts of DNA damage after drug treatment. These cells are the 
marginal cells in the stria vascularis and the outer hair cells in the organ of Corti, both 
indispensable components for the process of hearing. A corresponding observation 
was made in the second target tissue of cisplatin toxicity, the kidney, where the 
epithelium cells of the proximal tubules carried a similarly high adduct burden. By 
analyzing mice with a genetically reduced DNA repair capacity it was possible to 
pinpoint the platinum adducts as the relevant initial trigger for the drug-induced cell 
damage and the functional loss in both tissues.  
As all three affected cell types are characterized by the presence of multiple, highly 
active membrane transporters, it was hypothesized that aberrant import of cisplatin 
by one of these transporters may cause the vast levels of DNA damage. The in vivo 
screening for potential small molecule inhibitors identified diphenhydramine 
hydrochloride (DIPH) to efficiently reduce the excessive DNA platination in the target 
cells of cisplatin-treated mice, and thereby, significantly protect their hearing 
capability. 
To test whether the co-application of DIPH is specifically preventive for the cochlear 
and kidney target cells and does not reduce the therapeutic efficacy of cisplatin for 
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primary tumors a mouse model for human lung cancer was studied in detail.  Neither 
the formation of DNA adducts in the tumor cells nor the reducing effect of cisplatin 
with respect to number and volume of the tumors were negatively influenced by the 
concomitant DIPH treatment. The data strongly suggest a clinical applicability of this 
strategy, in particular as DIPH is an approved drug. 
Finally, the mouse lung cancer model was investigated for mechanisms underlying 
the development of non-responsiveness during repetitive treatment cycles with 
cisplatin. The cells in drug-resistant tumors accumulated much lower amounts of 
DNA platination as compared to tumors still responding to cisplatin chemotherapy, 
and time-resolved analyses hint to augmented DNA repair as the responsible 
mechanism. 
The results of this study contribute to a better understanding of the in vivo effects of 
cisplatin-based chemotherapies and may pave the way to circumvent some of the 
major clinical obstacles. 
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Zusammenfassung 
 
Cisplatin gehört zu den in der onkologischen Klinik am häufigsten verwendeten 
Zytostatika und wird beispielsweise sehr effektiv bei der Behandlung von 
Hodentumoren eingesetzt. Cisplatin ist zudem zentraler Bestandteil in Therapie-
Konzepten für eine Zahl anderer solider Tumore, wie Ösophagus- oder 
Lungenkarzinome. Neben der anti-neoplastischen Wirkung induziert Cisplatin aber 
auch eine Reihe schwerwiegender, oft Dosis-begrenzender Nebenwirkungen. Dazu 
zählt neben der Schädigung der Niere und des peripheren Nervensystems vor allem 
die ausgeprägte Toxizität im Innenohr mit nachfolgendem irreversiblem Hörverlust. 
Die molekularen Mechanismen dieser spezifischen Wirkung auf terminal-
differenzierte Normalzellen waren bisher unbekannt und wurden hier an verschieden 
Mausmodellen in vivo untersucht.  Eingesetzt wurden dazu vor allem 
immunanalytischen Nachweisverfahren zur quantitativen Messung von Cisplatin-
induzierten Schäden in der Kern-DNA einzelner Zellen.  
Dabei zeigte sich, dass es nach einer Cisplatin-Behandlung sowohl im Innenohr als 
auch in der Niere in bestimmten Zellarealen (Marginalzellen und äußere Haarzellen 
der Cochlea, Epithelzellen der proximalen Tubuli der Niere) zu einer extrem hohen 
Anreicherung von DNA-Läsionen kommt und dass diese Schäden ursächlich für die 
Funktionsverluste bei beiden Organe sind.  
Da dieses Schädigungsprofil sehr wahrscheinlich auf einem hochwirksamen, 
aberranten Import des Medikamentes durch physiologische Membrantransporter in 
den betroffenen Zellen  beruht, wurde im nächsten Schritt nach einem spezifischen 
Inhibitor für diesen Mechanismus gesucht. Mit Diphenylhydramin (DIPH) konnte ein 
solcher in vivo-wirksamer Inhibitor identifiziert werden, der Dosis-abhängig sowohl 
die Akkumulation von DNA-Schäden in den Zielzellen als auch den Cisplatin-
induzierten Funktionsverlust blockierte.   
An einem Mausmodell für das nicht-kleinzellige Lungenkarzinom (NSCLC) konnte 
anschließend gezeigt werden, dass eine effiziente pharmakologische Oto- und 
Nephroprotektion durch DIPH weder die DNA-Platinierung in primären Tumorzellen 
noch  die therapeutische Wirksamkeit einer Cisplatin-Behandlung negativ beeinflusst. 
Damit sind die wichtigsten Grundlagen für eine klinische Erprobung dieser neuen 
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Protektionsstrategie gelegt, da es sich bei DIPH um ein zugelassenes Medikament 
handelt. 
In einem weiteren Teilabschnitt dieser Arbeit wurden an dem NSCLC-Mausmodell 
auch die Mechanismen einer Cisplatin-Resistenz  genauer untersucht, da die 
molekularen Ursachen für das häufig auftretende klinische Therapieversagen beim 
behandelten Lungenkarzinom nicht genau verstanden sind. Es konnte hier erstmals 
nachgewiesen werden, dass nach mehrmaligen Behandlungszyklen die Zellen 
Therapie-refraktärer Tumore eine deutlich reduzierte Akkumulation von Cisplatin-
DNA-Schäden aufwiesen. Ursächlich dafür ist sehr wahrscheinlich eine selektiv 
gesteigerte DNA-Reparatur-Kapazität dieser Zellen. 
Die hier erhobenen Befunde tragen wesentlich zum besseren Verständnis der 
Wirkungsmechanismen einer Therapie mit Platin-Zytostatika bei und bieten damit 
wichtige Ansatzpunkte für einen effizienteren klinischen Einsatz dieser Medikamente. 
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